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With the rapid increase in the elderly population, the number of Americans 
afflicted with vision impairment due to ocular disease is projected to rise substantially 
by the year 2020.  Ocular disorders are becoming a major public health problem, and 
efforts have increased in recent years to develop methods of efficient drug delivery.  
Currently, the most effective method for treating serious ocular disorders is to inject 
drug solutions directly into the vitreous.  However, injecting in this manner carries a 
high risk of severe side effects.  As a safer alternative, researchers in recent years 
have been investigating transscleral drug delivery, in which the drug is administered 
to the outer coat of the eye.  Various methods of transscleral drug delivery have been 
proposed, but it is still clinically not as effective as intravitreal drug delivery.  In 
order to design improved transscleral drug delivery systems, the ocular barriers to 
drug transport must be accurately understood.   
  
While various barrier types have been identified in the eye, the significance 
and contribution of individual barriers have not been investigated and are still widely 
unknown.  A reason for this lack of understanding is due to the inability to acquire 
concentration measurements in the eye in vivo.  In this study, magnetic resonance 
imaging (MRI) was employed to obtain drug concentration measurements in vivo 
after transscleral drug delivery. 
To address the current needs of the ocular drug delivery community, several 
goals have been achieved in this work: (1) to evaluate transscleral drug delivery in 
vivo using MRI, (2) to assess MRI as a technique for evaluating drug delivery in the 
eye, and (3) to better understand the significance of individual barriers in the eye by 
quantitatively analyzing experimental (MRI) data and by pharmacokinetic modeling.  
While encompassing many advantages, it is found that MRI has limitations in spatial 
and temporal resolution that may restrict its use in measuring parameters with low 
sensitivity.  However, the MRI results in parallel with analysis from the 
pharmacokinetic model give new insight into the barriers to drug transport in the eye.   
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
ANALYSIS OF DRUG DELIVERY IN THE EYE USING MAGNETIC 
RESONANCE IMAGING  
 
 
 
By 
 
 
Heekyong Stephanie Kim 
 
 
 
 
 
Dissertation submitted to the Faculty of the Graduate School of the  
University of Maryland, College Park, in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
2007 
 
 
 
 
 
 
 
 
 
 
Advisory Committee: 
Professor Nam Sun Wang, Chair 
Dr. Robert J. Lutz 
Professor Srinivasa R. Raghavan 
Professor Yang Tao 
Professor Evanghelos Zafiriou 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Copyright by 
Heekyong Stephanie Kim 
2007 
 
 
 
 
 
 
 
 
 
 
 
 
 ii 
 
Dedication 
 
To those who have faithfully supported and encouraged me through the entire course 
of my thesis work by covering every detail in prayer.   
 
 
 iii 
 
Acknowledgements 
 
 I have had the honor and privilege to work with many advisors and 
collaborators from the University of Maryland and the National Institutes of Health, 
all of whom have contributed to the successful completion of this dissertation.  I am 
grateful for the support from my advisor, Dr. Nam Sun Wang, who graciously gave 
me this opportunity to pursue a research project at the NIH, which has been an 
invaluable experience.  I also thank Dr. Michael Robinson for being a mentor and for 
teaching me the current needs in ocular drug delivery.  Dr. Karl Csaky has 
contributed significantly to this project financially and also by providing strong 
guidance and direction from an ophthalmology viewpoint.   
 I also appreciate the support from the senior scientists at the Drug Delivery 
and Kinetics Resource within the National Institute of Biomedical Imaging and 
Bioengineering at the NIH.  Dr. Robert Lutz has been a wonderful research advisor 
and I am grateful to have been able to work under his supervision as I have learned 
how to approach drug delivery and pharmacology as a chemical engineer.  I am also 
thankful for Dr. Peter Bungay, Dr. Robert Dedrick, and Dr. Paul Morrison, who have 
always been extremely kind and available to help with my questions and 
interpretation of data.  I thank Dr. Bungay especially for his direction and guidance in 
pharmacokinetic modeling. 
 I would also like to acknowledge the technical assistance I have received from 
Dr. Craig Galban and Dr. Martin Lizak.  Craig has been an incredible help in 
processing and analyzing image data, and Marty has been very kind in helping us 
 
 iv 
 
during our MR imaging sessions.  I would also like to thank the staff at the animal 
MRI facility at the NIH, as I have greatly appreciated their eager willingness always 
to help.  I thank Dr. Ginger Tansey and the veterinary technicians: Denise Parker, 
Mark Lawson, Carrie Silver, Beth Case, Mark Szarowicz and Chris Hillman for their 
flexibility and faithful support and care of our rabbits.  They have always been very 
willing to assist with our animal experiments, which has been a tremendous help.  
 I am also thankful for the other members of Wang lab, especially for offering 
their ideas and suggestions for my research.  I have thoroughly enjoyed our lab 
meetings, which have helped me broaden my knowledge of current chemical 
engineering research and have also refined my critical thinking skills as a scientist.   
 Finally, I would like to thank the members of this dissertation committee for 
their input and recommendations from the research proposal, which has enabled 
greater focus and direction for this dissertation. 
 
 
 v 
 
Table of Contents 
 
 
Dedication ..................................................................................................................... ii 
Acknowledgements...................................................................................................... iii 
Table of Contents.......................................................................................................... v 
List of Tables ................................................................................................................ x 
List of Figures .............................................................................................................. xi 
Chapter 1: Introduction ................................................................................................. 1 
1.1. Eye Anatomy ..................................................................................................... 2 
1.2. Drug Delivery Methods for Posterior Segment Disorders................................. 4 
1.3. Transport Barriers during Transscleral Drug Delivery...................................... 8 
1.3.1. Static Barriers.............................................................................................. 9 
1.3.2. Dynamic Barriers ...................................................................................... 14 
1.3.2.1.  Conjunctival/episcleral clearance ..................................................... 14 
1.3.2.2.  Choroidal clearance .......................................................................... 17 
1.3.2.3.  Clearance by bulk fluid flow............................................................. 18 
1.3.2.4.  RPE transporter proteins ................................................................... 21 
1.3.3.  Metabolic Barriers ................................................................................... 23 
1.3.3.1.  Cytochrome P-450 ............................................................................ 24 
1.3.3.2.  Lysosomal enzymes .......................................................................... 24 
1.3.4.  Concluding Remarks................................................................................ 26 
1.4. Methods of Ocular Pharmacokinetic Data Measurement ................................ 28 
1.4.1. Traditional Methods.................................................................................. 28 
 
 vi 
 
1.4.2. Non-invasive methods .............................................................................. 30 
1.5. Project Overview ............................................................................................. 32 
Chapter 2: Calibration of Contrast Agents.................................................................. 34 
2.1. Introduction...................................................................................................... 34 
2.1.1. MRI Physics.............................................................................................. 34 
2.1.2. Pulse Sequence.......................................................................................... 39 
2.1.3. Contrast Agents......................................................................................... 40 
2.1.4. Factors Affecting MR Images................................................................... 41 
2.1.5. Conversion of Signal Intensity to Concentration...................................... 42 
2.2. Methods............................................................................................................ 44 
2.3. Results.............................................................................................................. 45 
2.4. Discussion ........................................................................................................ 49 
2.5. Conclusion ....................................................................................................... 51 
Chapter 3: Assessment of Sustained Drug Delivery by Infusion ............................... 52 
3.1. Introduction...................................................................................................... 52 
3.2. Methods............................................................................................................ 53 
3.2.1. Animal Setup ............................................................................................ 53 
3.2.2. MRI Setup................................................................................................. 56 
3.2.3. Image Analysis.......................................................................................... 58 
3.2.4. Histology Study ........................................................................................ 60 
3.3. Results.............................................................................................................. 60 
3.3.1. Subconjunctival Infusion .......................................................................... 61 
3.3.2. Intrascleral Infusion .................................................................................. 63 
 
 vii 
 
3.3.3. Suprachoroidal Clearance ......................................................................... 65 
3.3.4. Histological Examination.......................................................................... 68 
3.4. Discussion ........................................................................................................ 70 
3.4.1. Assessment of Sustained Drug Delivery by Continuous Infusion............ 70 
3.4.2. Assessment of Suprachoroidal Delivery................................................... 71 
3.4.3. Advantages and Limitations in using MRI for Drug Delivery Assessment
............................................................................................................................. 73 
3.5. Conclusion ....................................................................................................... 76 
Chapter 4: Drug Elimination Kinetics after Subconjunctival Injection...................... 77 
4.1. Introduction...................................................................................................... 77 
4.2. Methods............................................................................................................ 78 
4.2.1. Animal Setup ............................................................................................ 78 
4.2.2. MRI Setup................................................................................................. 80 
4.2.3. Image Analysis.......................................................................................... 82 
4.2.4. Cryotherapy Procedure ............................................................................. 83 
4.3. Results.............................................................................................................. 84 
4.4. Discussion ........................................................................................................ 94 
4.4.1. Gd-DTPA vs. Gd-albumin ........................................................................ 94 
4.4.2. Quantitation of MRI Results..................................................................... 96 
4.4.3. Effect of Injection Volume ....................................................................... 97 
4.4.4. Effect of Cryotherapy ............................................................................... 98 
4.4.5. Limitations in DCE-MRI Technique ........................................................ 99 
4.5. Conclusion ..................................................................................................... 100 
 
 viii 
 
Chapter 5: A Model of Subconjunctival Drug Delivery........................................... 101 
5.1. Introduction.................................................................................................... 101 
5.2. Methods.......................................................................................................... 105 
5.2.1. Model Geometry ..................................................................................... 105 
5.2.2. Model Parameters ................................................................................... 108 
5.2.2.1. Governing equation.......................................................................... 108 
5.2.2.2. Diffusion coefficients....................................................................... 110 
5.2.2.3. Clearance rates ................................................................................. 111 
5.2.2.3. Boundary and Initial conditions....................................................... 114 
5.3. Results............................................................................................................ 115 
5.3.1. Post mortem ............................................................................................ 115 
5.3.2. In vivo...................................................................................................... 122 
5.3.3. Effect of thresholding ............................................................................. 127 
5.3.4. Sensitivity analysis.................................................................................. 128 
5.3.4. Conjunctival vs. choroidal clearance ...................................................... 132 
5.3.5. Unidirectional Implant ............................................................................ 133 
5.4. Discussion ...................................................................................................... 136 
5.4.1. Model vs. MRI results............................................................................. 136 
5.4.2. Concentration levels in individual tissues............................................... 138 
5.4.3. Sensitivity Analysis ................................................................................ 139 
5.4.4. Conjunctival vs. choroidal clearance ...................................................... 142 
5.5. Conclusion ..................................................................................................... 142 
Chapter 6: Summary and Recommendations for Future Work ................................ 143 
 
 ix 
 
6.1. Project Summary............................................................................................ 143 
6.2.  Recommendations for Future Work.............................................................. 144 
Chapter 7: Appendix ................................................................................................. 147 
Bibliography ............................................................................................................. 150 
 
 
 x 
 
List of Tables 
 
Table  1-1.  Summary of the effects on ex vivo permeability in ocular tissues with 
various solute physicochemical properties. ................................................................ 13 
Table  4-1.  Summary of average rate constants ± SD acquired in vivo and post 
mortem. ....................................................................................................................... 87 
Table  4-2.  Results from the Mann-Whitney U test for U(0.05). ................................89 
Table  5-1.  Tissue thickness values used in model. .................................................. 107 
Table 5-2.  Model values of extracellular void volume fraction............................... 107 
Table 5-3.  Model parameters: diffusion coefficients. .............................................. 110 
Table 5-4.  Literature values and calculated values of PS. ....................................... 110 
Table 5-5.  Literature values of Q............................................................................. 112 
Table 5-6.  Calculated clearance rate constants for in vivo models. ......................... 113 
Table 5-7.  Model parameters varied for sensitivity analysis. .................................. 129 
Table 5-8.  Summary of mass clearance values (k) from model simulations. .......... 132 
Table 5-9.  Comparison of Rp and Rc in the conjunctiva and choroid. ..................... 140 
 
 
 
 
 
 xi 
 
List of Figures 
 
Figure  1-1.  The anatomy of the human eye. ................................................................ 3 
Figure  1-2.  Methods of ocular drug delivery. .............................................................. 5 
Figure  1-3.  Subconjunctival Delivery.......................................................................... 6 
Figure  1-4.  Penetration pathway of drugs after transscleral delivery. ......................... 8 
Figure  1-5.  Static and dynamic barriers of the eye. ................................................... 10 
Figure  1-6.  The two-chamber Ussing apparatus. ....................................................... 11 
Figure  1-7.  Illustration of the conjunctival lymphatic network. ................................ 15 
Figure  1-8.  Clearance of dye through conjunctival lymphatics. ................................ 16 
Figure  1-9.  Clearance mechanisms by bulk fluid flow present during transscleral 
delivery. ...................................................................................................................... 19 
Figure  1-10.  Levels of lysosomal enzymes in ocular tissues..................................... 26 
Figure  1-11.  Schematic of tissue sampling sites for ocular drug distribution 
assessment................................................................................................................... 29 
Figure 2-1.  Random alignment of atoms in the absence of an applied magnetic field.
..................................................................................................................................... 34 
Figure 2-2.  Alignment of atoms in the presence of an applied magnetic field Bo. .... 35 
Figure 2-3.  The longitudinal axis and the transverse plane. ...................................... 36 
Figure 2-4.  The electromagnetic spectrum. ............................................................... 37 
Figure 2-5.  The intensity curve for T1 relaxation. ..................................................... 38 
Figure 2-6.  The intensity curve for T2 relaxation. ..................................................... 39 
Figure 2-7.  The effect of T1 on signal intensity at a specified TR............................. 41 
 
 xii 
 
Figure 2-8.  Calibration showing the linear relationship between inverse T1 relaxation 
time and MnEDTA2- concentration............................................................................. 43 
Figure 2-9.  MR image of Gd-DTPA phantoms in PBS. ............................................ 45 
Figure 2-10.  Gd-DTPA calibration showing the relationship between concentration 
and signal intensity. .................................................................................................... 46 
Figure 2-11.  Gd-DTPA calibration in PBS................................................................ 47 
Figure 2-12.  Gd-DTPA calibration in 2% HPMC. .................................................... 48 
Figure 2-13.  Gd-albumin calibration in PBS. ............................................................ 49 
Figure 3-1.  Intrascleral osmotic pump implantation in a rabbit eye. ......................... 53 
Figure 3-2.  Photograph of IV catheter. ...................................................................... 55 
Figure 3-3.  Custom-built surface coil placed over the rabbit eye.............................. 56 
Figure 3-4.  Positioning of slices in O1 and O2 shown on a schematic eye. .............. 57 
Figure 3-5.  T1 weighted MR image of the eye in O2 before infusion. ...................... 61 
Figure 3-6.  MR images of subconjunctival vs. intrascleral infusion. ........................ 62 
Figure 3-7.  Spread of Gd-DTPA measured in the suprachoroidal space................... 64 
Figure 3-8.  Time series MR images during intrascleral infusion. ............................. 65 
Figure 3-9.  Time series MR images of suprachoroidal clearance. ............................ 66 
Figure 3-10.  Suprachoroidal clearance after 1 and 10 µl/min intrascleral infusion. . 67 
Figure 3-11.  Histological images of the suprachoroidal space. ................................. 69 
Figure 4-1.  Photograph of subconjunctival catheter placement................................. 80 
Figure 4-2.  Rabbit setup in magnet............................................................................ 81 
Figure 4-3.  MRI scans of 200 μl Gd-DTPA. ............................................................. 85 
Figure 4-4.  MRI scans of 600 μl Gd-DTPA. ............................................................. 86 
 
 xiii 
 
Figure 4-5.  Plots comparing Gd-DTPA in vivo and post mortem.............................. 88 
Figure 4-6.  MRI scans of 200 μl Gd-albumin............................................................ 90 
Figure 4-7.  Plots comparing Gd-DTPA and Gd-albumin.......................................... 92 
Figure 4-8.  Sectioned cryo area after H&E staining.................................................. 93 
Figure 5-1.  A simple compartmental pharmacokinetic model of subconjunctival 
injection..................................................................................................................... 103 
Figure 5-2.  A proposed compartmental pharmacokinetic model of subconjunctival 
injection..................................................................................................................... 104 
Figure 5-3.  A distributed pharmacokinetic model of subconjunctival injection. .... 104 
Figure 5-4.  Model geometry in r-z plane. ................................................................ 106 
Figure 5-5.  Meshed geometry in r-z plane............................................................... 108 
Figure 5-6.  Boundary conditions. ............................................................................ 115 
Figure 5-7.  Model result at t=0 min post-injection (initial condition)..................... 116 
Figure 5-8.  Concentration changes of Gd-DTPA with time and space in the post 
mortem model. .......................................................................................................... 117 
Figure 5-9.  Concentration profiles from the post mortem model of Gd-DTPA through 
the center axis of symmetry, r=0. ............................................................................. 118 
Figure 5-10.  Increased magnification of concentration profiles shown in Figure 5-9.
................................................................................................................................... 119 
Figure 5-11.  A comparison of the mass clearance of Gd-DTPA from the post mortem 
model and the MRI data............................................................................................ 120 
Figure 5-12.  A comparison of the distribution volume of Gd-DTPA from the post 
mortem model and the MRI data. ............................................................................. 121 
 
 xiv 
 
Figure 5-13.  Concentration changes of Gd-DTPA with time and space in the in vivo 
model......................................................................................................................... 122 
Figure 5-14.  Concentration profile results from the in vivo model of Gd-DTPA 
through the center axis of symmetry, r=0. ................................................................ 123 
Figure 5-15.  Increased magnification of concentration profiles shown in Figure 5-14.
................................................................................................................................... 124 
Figure 5-16.  A comparison of the mass clearance of Gd-DTPA from the in vivo 
model and the MRI data............................................................................................ 125 
Figure 5-17.  A comparison of the distribution volume of Gd-DTPA from the in vivo 
model and the MRI data............................................................................................ 126 
Figure 5-18.  Individual average tissue concentrations of Gd-DTPA from the in vivo 
model......................................................................................................................... 128 
Figure 5-19.  Effect of varying the diffusion coefficient of various tissues on mass 
clearance rate. ........................................................................................................... 130 
Figure 5-20.  Effect of doubling RPE permeability on tissue concentration. ........... 131 
Figure 5-21.  Concentration profiles from the unidirectional model simulation. ..... 134 
Figure 5-22.  Comparison of average concentration levels in target tissues after 
delivery by unidirectional implant and bolus injection............................................. 135 
Figure 5-23.  The effect of T2 on signal intensity at a specified TE. ........................ 136 
 
 
 1 
 
Chapter 1: Introduction 
 
Due to the rapidly increasing elderly population, ocular disorders leading to 
vision impairment is becoming a major public health problem [1].  The number of 
Americans diagnosed with age-related macular degeneration (AMD), a disease 
responsible for the majority of cases of blindness, will increase by 50% to 2.95 
million in the year 2020 [2].  AMD and other leading causes of vision loss such as 
diabetic retinopathy, endophthalmitis, and retinitis pigmentosa are currently difficult 
to treat [3,4] because they affect tissues in the posterior segment of the eye, such as 
the choroid and retina (Fig. 1-1).  Drug delivery to the posterior segment has 
remained a challenge as most drugs fail to reach therapeutic levels in this region after 
topical and systemic administration.   
As ocular disorders become more prevalent, the need for more effective 
therapies and treatments will increase.  Many researchers in ophthalmology have been 
interested in developing new methods for more effective drug delivery to the eye.  
While numerous novel drug delivery systems have been proposed, many are unable to 
deliver therapeutic drug levels to target ocular tissues in a safe and minimally 
invasive manner.   
The amount of drug that is delivered to a desired area can be affected by 
factors such as drug transport barriers and clearance mechanisms.  Despite the 
numerous efforts in the development of new ophthalmic drug delivery systems, the 
ocular elimination mechanisms and the rate of drug clearance are largely unknown.  
By understanding how drugs are eliminated in the eye, the design of drug delivery 
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systems can be improved with greater efficiency.  The aim of this research is to 
investigate how drugs are eliminated in the eye after ocular drug delivery by using 
magnetic resonance imaging and drug transport modeling.  
 
1.1. Eye Anatomy 
 The eye is composed of two tunics that envelop the anterior and posterior 
segments.  The anterior segment is capped by the cornea, and the posterior segment is 
bound by the sclera, choroid, and retina (Fig. 1-1).  These thin tunics envelop the 
vitreous body which is a gelatinous mass that occupies most of the ocular volume.  
The sclera is known as the white coat of the eye which is avascular and is primarily 
composed of collagen fibrils.  The choroid is a highly vascular layer which possesses 
the fastest rate of blood flow in the entire human body.  Blood flow through the 
choroid provides necessary nutrients to the underlying retinal cells and also acts as a 
sink for heat dissipation.  The retina is a multi-cellular layer responsible for many of 
the visual processes of the eye.  The macula is an oval region of the posterior retina 
which is specialized for central vision, and is a common target tissue in ocular drug 
delivery.  
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Figure  1-1.  The anatomy of the human eye. 
From reference [5]. 
 
 
The conjunctiva is a thin, opaque, filmy tissue that extends up to the equator 
of the posterior segment and folds up to line the inside of the upper and lower eyelids, 
forming the upper and lower conjunctival sac.  It is a vascular tissue that has an 
extensive network of blood and lymphatic vessels.   
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1.2. Drug Delivery Methods for Posterior Segment Disorders 
Four methods of drug delivery have been investigated for treatment of 
posterior segment disorders: topical, systemic, intravitreal, and periocular [3].  Figure 
 1-2 illustrates some of these drug delivery methods.  While topical eye drops (Figure 
 1-2A) are easy to use and are non-invasive, less than 3% of the instilled drug has been 
found to penetrate the anterior segment due to low retention times in the conjunctival 
sac and rapid drainage from the ocular surface [6].  Topical eye drops are the most 
common method of ophthalmic treatment, but they are typically used in treating 
anterior disorders since drug concentrations in the posterior segment are typically 
below therapeutic levels [7].  Systemic injections of drugs also yield low drug 
concentrations in the eye because of the blood-ocular barriers that restrict the 
movement of drugs from the bloodstream into the surrounding tissues [8,9].  
Unfavorable side effects usually result from toxicity because high systemic doses are 
required to achieve therapeutic levels in the eye.  Intravitreal injections (Figure  1-2G) 
and implants (Figure  1-2F) can be administered directly into the vitreous to allow 
higher amounts of drug to reach the posterior tissues of the eye but the invasive 
surgical procedure may produce severe side effects such as retinal detachment, 
hemorrhage, and cataracts [3].  As a safer alternative, periocular delivery methods can 
be used, which require administering drugs to the outer tissues of the eye.  This is 
typically accomplished by injecting (Figure  1-3) or implanting (Figure  1-2C) drugs 
underneath the conjunctiva, forming a subconjunctival drug depot.  The elastic nature 
of the conjunctiva allows a localized depot to form after a drug solution injection, 
offering the potential for long-term sustained release.    
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Figure  1-2.  Methods of ocular drug delivery.   
From reference [10]. 
 
 
Subconjunctival injections are a form of transscleral delivery, a method which 
requires drugs to penetrate across the sclera in order to reach the underlying target 
tissues such as the choroid, retina and vitreous [4].  Transscleral delivery is emerging 
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as an attractive method for ocular drug delivery because it is a less invasive and a 
safer alternative to other delivery methods, and also permits localized, sustained-
release delivery of drugs to the posterior segment of the eye [3].  Subconjunctival 
injections of celecoxib, for example, yields greater delivery to the retina than 
systemic administration [11].  
 
 
 
Figure  1-3.  Subconjunctival Delivery.   
Left: Anatomy of tissues involved during transscleral delivery.  Top right: Photograph 
taken after subconjunctival injection in an albino rabbit eye.  The conjunctiva is an 
elastic tissue that permits the formation of a local depot. 
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Methods of transscleral drug delivery range from drug solution injections to 
polymeric implants.  Microparticles administered subconjunctivally have been 
formulated for the sustained release of drugs such as celecoxib [12] and budesonide 
[13] to maintain therapeutic retinal levels.  Injectable gels with sustained release of 
drugs have been administered subconjunctivally [14,15].  Polymeric implants have 
been constructed as subconjunctival [16], episcleral [17], and intrascleral [18,19] 
discs.  Osmotic pumps have also been utilized to intrasclerally infuse continuous 
amounts of drug into the eye [20,21].  
Although there has been great interest in the development of transscleral drug 
delivery systems, transscleral delivery is still not as clinically effective as intravitreal 
delivery in treating retinal disorders [22,23].  The only treatments available for AMD 
(Lucentis, Avastin, and Macugen) are currently administered as intravitreal injections.  
During transscleral delivery, drug molecules must cross several layers of tissue before 
reaching the vitreous (Figure  1-4), and a very steep concentration gradient from the 
sclera to the vitreous is usually established.  This steep gradient is due to barriers in 
transport that hinder drug molecules from successfully reaching the inner ocular 
tissues. 
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Figure  1-4.  Penetration pathway of drugs after transscleral delivery. 
 
 
1.3. Transport Barriers during Transscleral Drug Delivery 
Three types of barriers hindering transscleral drug delivery have been 
described in the current literature: static, dynamic, and metabolic [24].  Static barriers 
are created by the structural features of the ocular tissues which pose a physical 
barrier to drug diffusion (Figure  1-5).  Dynamic barriers are active clearance 
mechanisms of drug elimination through blood and lymphatic vessels, bulk fluid flow 
due to intraocular drainage, and also include the transporter proteins of the retinal 
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pigment epithelium (RPE).  Metabolic barriers also exist in the eye, and may reduce 
drug penetration to the retina by degradation.   
 
1.3.1. Static Barriers 
The sclera is a matrix composed of proteoglycans and collagen fibers that can 
hinder the penetration of drug molecules through the tissue.  The choroid and the 
underlying Bruch’s membrane, a complex composition of lipids and lipoproteins, can 
also impede the movement of drug molecules.  The RPE provides a cellular barrier 
with tight junctions, effectively reducing paracellular transport.   
The diffusional barrier of these tissues to drug molecules has been most 
widely studied ex vivo by using the two-chamber Ussing type apparatus (Figure  1-6).  
The Ussing system measures the permeability of solutes across a membrane mounted 
between the two chambers.  Permeability is reported in units of cm/s, and can be 
understood as the velocity of the molecule diffusing across a tissue in response to a 
concentration gradient [25].   
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Figure  1-5.  Static and dynamic barriers of the eye. 
The static barriers (sclera, choroid, and retinal pigment epithelium) present during 
transscleral drug delivery.  Clearance pathways present in the conjunctiva/episclera 
and choroid during transscleral delivery.   
 
 
 
 
 
 11 
 
 
Figure  1-6.  The two-chamber Ussing apparatus. 
From reference [26].  
 
 
Several factors influence the tissue permeability of molecules.  Tissue 
permeability has been shown to have a strong dependence on molecular weight, with 
larger molecules having lower permeabilities than smaller molecules in the sclera 
[27-31].  Permeability has been shown to decrease roughly exponentially with 
molecular radius in the sclera [28,32], choroid and RPE [33].  Table 1-1 summarizes 
the effect of various physicochemical properties of solutes on the permeability of 
ocular tissues.  The permeability of the Bruch’s membrane and choroid (BC) has 
always been studied in tandem due to the difficulty of separating the two tissue layers 
[34].  The RPE, however, can be easily removed and its permeability characteristics 
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are understood by comparing tissue permeability values with and without RPE 
removal. 
Increase in solute lipid solubility was also shown to lower scleral permeability 
[26,35,36], as hydrophilic compounds may diffuse through the aqueous media of 
proteoglycans in the fiber matrix pores more easily than lipophilic compounds [35].  
Increasing solute lipophilicity also decreases the permeability of the choroid [36] but 
increased the permeability of the RPE [33].  This suggests that the permeability of the 
RPE increases with increasing lipophilicity.  Solutes with negative charges have been 
found to have higher permeabilities than those with positive charges in sclera [36,37].  
Proteoglycans in the sclera are negatively charged [38], which may contribute to the 
binding of positively charged molecules.   
The ex vivo permeability of the sclera has been extensively reported in the 
literature.  The permeability for a number of molecules has been measured including 
dextrans [30] and PEG molecules [29] of various molecular weights, antibiotics [39], 
oligonucleotides [40], retinal anti-angiogenic molecules [41], and lipophilic 
compounds [35,36].  Permeability studies of the Bruch’s membrane-choroid and the 
RPE, however, are not as extensive as that of the sclera.  Additional permeability 
studies are necessary to establish the relative resistance of the BC and RPE for a 
variety of solutes.   
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Physicochemical 
property 
Sclera BC BC-RPE 
Molecular radius 
Exponential 
decrease with 
increasing radius 
[28,32] 
Decrease with 
increasing 
molecular weight 
[42] 
Exponential 
decrease with 
increasing 
molecular radius 
[33] 
Lipophilicity 
Decrease with 
increase in 
lipophilicity 
[26,35,36] 
Decrease with 
increase in 
lipophilicity [36] 
Increase with 
increase in 
lipophilicity [33] 
Charge 
Increase with 
negatively charged 
solutes [36,37] 
Increase with 
negatively charged 
solutes [36] 
Not studied 
Table 1-1.  Summary of effects on ex vivo permeability in ocular tissues with 
various solute physicochemical properties.  
 
 
Most studies on transport barriers affecting transscleral drug delivery have 
focused on the determination of permeability values of ocular tissues.  Permeability 
values are helpful for comparing diffusional resistances of one tissue to another and 
can also be used to calculate the diffusion coefficients of drugs.  However, 
permeability values or diffusion coefficients alone cannot be used to determine the 
transport of drugs in the eye, since dynamic and metabolic barriers can also affect 
drug distribution.         
 
 
 14 
 
1.3.2. Dynamic Barriers 
 Tissue permeabilities measured ex vivo do not take into account the effects of 
dynamic barriers that are present in vivo.  In vivo studies are required to examine the 
dynamic barriers, which include clearance through lymphatic and blood vessels, bulk 
fluid flow, and the active transport mechanisms of RPE transporter proteins.  Some 
dynamic barriers cease post mortem, and drug levels in some ocular tissues may be 
overestimated when measurements are obtained ex vivo.  A summary of experiments 
investigating the effect of dynamic barriers on transscleral drug delivery in vivo is 
given.  Rabbits have typically been used for in vivo clearance studies, and constitute 
the majority of the reports described below.   
 
1.3.2.1.  Conjunctival/episcleral clearance 
 The conjunctiva is well-vascularized in most mammals with considerable 
variability in vascularity present in the episclera between species (Fig. 1-7) [43-45].  
Several studies have been performed to demonstrate that drug present in the 
conjunctival and episcleral tissues may be cleared through blood and lymphatic 
vessels.   
 Ocular lymphatic vessels have been investigated in humans [46-48] as well as 
in rabbits [49].  Radioactive tracers injected subconjunctivally have been detected in 
the cervical lymph nodes [50].  It has been estimated that the 131I-albumin-Evans blue 
complex migrates to the lymph nodes of the neck within six minutes after 
subconjunctival injection [51].  Figure 1-8 shows the immediate filling of lymphatic 
vessels after subconjunctival injection of a dye solution.   
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Figure  1-7.  Illustration of the conjunctival lymphatic network. 
From reference [52].  
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Figure  1-8.  Clearance of dye through conjunctival lymphatics. 
From reference [48].  
 
 
 The higher retention of subconjunctivally injected microparticles compared to 
nanoparticles [53] and the higher half-life of albumin compared to 22Na [54] in 
subconjunctival tissue suggest that molecular size may affect the rate of 
conjunctival/episcleral clearance.  Reports of the effect of various physicochemical 
factors on drug clearance through lymphatic and blood vessels are lacking, and 
further studies are needed to have a clearer understanding of the importance of these 
mechanisms.   
 Studies have also demonstrated that selective elimination of the 
conjunctival/episcleral clearance mechanisms result in higher amounts of intraocular 
drug penetration.  Rabbits that received a sub-Tenon’s injection of triamcinolone 
acetonide with an incised ‘conjunctival window’ created to inhibit local blood and 
lymphatic clearance in the conjunctiva had higher levels of drug in the vitreous than 
rabbits that did not have the incision [55].  Experiments were also performed to 
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compare the delivery of sodium fluorescein to the retina by periocular injection and a 
unidirectional episcleral exoplant.  The exoplant allowed release of dye on the 
episcleral side but not on the conjunctival side.  Higher amounts of sodium 
fluorescein were detected in the retina after delivery using a unidirectional episcleral 
exoplant than after periocular injection [56].  The results from these studies suggest 
that conjunctival/episcleral clearance mechanisms play a significant role in reducing 
intraocular drug penetration.  
 
1.3.2.2.  Choroidal clearance 
 Uptake by the rapid blood flow of the choroid is another mechanism by which 
drugs can be eliminated during transscleral delivery, hindering transport to the retina.  
Due to its high blood perfusion, the choroid is usually regarded as a sink in which the 
drug concentration is assumed to be zero when modeling drug transport in ocular 
tissues [57,58].   
 Systemic drug levels can be measured by acquiring blood samples, and 
tilisolol has been shown to be rapidly absorbed into the bloodstream after periocular 
injection [59].  But the effect of choroidal clearance cannot be accurately determined 
by systemic drug measurements since drugs cleared from the conjunctival blood 
vessels as well as the choroidal vasculature are found in the bloodstream.  Drugs 
removed by lymphatic vessels can also contribute to systemic levels since the 
interstitial fluid is returned to the circulatory system after filtration through lymph 
nodes.   
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 Cryotherapy is one method that has been used to locally eliminate choroidal 
blood flow.  A single freeze/thaw cycle with cryotherapy forms a chorioretinal scar 
but leaves the conjunctiva and sclera intact [55].  Sub-Tenon’s injections of 
triamcinolone acetonide were performed in rabbits at least 1 month after receiving 
cryotherapy to allow time for the conjunctiva and sclera to recover and for maturation 
of the chorioretinal scar.  Rabbits that received cryotherapy did not have higher 
amounts of triamcinolone acetonide in the vitreous after sub-Tenon’s injection 
compared to those that received cryotherapy [55].  This study suggests that choroidal 
blood flow may not significantly contribute to drug elimination during transscleral 
delivery.   
 
1.3.2.3.  Clearance by bulk fluid flow 
 Convective fluid flow in the eye may also contribute to the reduced 
penetration of drug molecules after transscleral delivery.  Drug molecules can be 
carried along with bulk fluid flows present in ocular tissues and are ultimately cleared 
mostly through the choroidal or conjunctival vasculature.   
 
 1.  Uveoscleral outflow 
 The uveoscleral outflow pathway is also known as the unconventional route 
[60] for aqueous humor drainage.  Aqueous humor flows from the ciliary body into 
the posterior chamber, through the pupil, and into the anterior chamber.  It is then 
drained either through the trabecular meshwork into Schlemm’s canal and aqueous 
veins (conventional pathway) or directly through the ciliary body and into the 
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suprachoroidal space (unconventional pathway).  From the suprachoroidal space, the 
aqueous humor flows through scleral channels [61-63] and is cleared by conjunctival 
lymphatics (Fig. 1-9, uveoscleral flow inset).  Studies involving the  injection of 131I-
albumin-Evans blue into the suprachoroid demonstrated that most of the labeled 
albumin had passed out through the sclera and drained from the conjunctiva through 
lymphatic vessels and eventually into the systemic blood circulation [64,65].   
 
 
Figure  1-9.  Clearance mechanisms by bulk fluid flow present during 
transscleral delivery. 
P = pressure.  From reference [24]. 
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 The uveoscleral pathway is currently not well understood because there are no 
methods for determining uveoscleral outflow directly and in a non-invasive manner 
[66].  It is known that the contribution of uveoscleral drainage on the total aqueous 
humor outflow differs widely among various species.  Uveoscleral drainage has been 
reported to be in the range of 3 to 8% in rabbits [67] and up to 80% in mice [68].  
Values ranging from 4 to 60% have been reported in humans, and the effect of aging 
on uveoscleral outflow [69] must also be taken into account.  While uveoscleral 
outflow has previously been regarded as a minor route for aqueous humor drainage, 
the large values reported for uveoscleral outflow in humans indicate that it may play a 
more significant role.    
 The uveoscleral pathway may hinder the transport of drugs during transscleral 
delivery since it generates an outward bulk flow of fluid from the suprachoroidal 
space.  Some drug molecules may be carried along with the convective current of 
aqueous humor, eventually being cleared by the conjunctival vasculature.  Fluid and 
small particles can pass out directly through the scleral tissue [70], while larger 
particles exit the suprachoroid via scleral emissary channels found along the blood 
vessels and nerves that pierce the sclera [61].  
 
 2.  Hydrostatic and osmotic pressure 
 While most of the fluid produced by the ciliary body leaves the eye by the 
aqueous humor drainage routes, some is cleared by passing through the vitreous, 
retina, pigment epithelium into the choroid.  This flow of fluid maintains the 
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attachment of the retina to the pigment epithelium, and is mainly created by the 
difference between the osmotic pressures of the choroid and the vitreous [71,72].  The 
choroid is well vascularized, and is high in protein content.  The osmotic pressure of 
the choroid in rabbits has been calculated to be about 12-14 mmHg [73].  While the 
choroid has an osmotic pressure similar to that of blood, the vitreous humor has an 
osmotic pressure lower than that of blood (near 0 mmHg).  This difference in osmotic 
pressure between the choroid and the vitreous generates fluid flow towards the 
choroid (Fig. 1-9, osmotic flow inset).   
 The hydrostatic pressure difference between the suprachoroid and the 
episcleral tissue also contributes to outward bulk fluid flow [74].  At an IOP of 15 
mmHg, the hydrostatic pressure of the posterior suprachoroidal space in cynomolgus 
monkeys was measured as 3.7 ± 0.4 mmHg below the IOP [75].  There is a 
hydrostatic pressure difference of about 12 mmHg between the suprachoroid and the 
episcleral tissue, which serves as a driving force for outward bulk fluid flow. 
 
1.3.2.4.  RPE transporter proteins 
 The RPE is responsible for regulating the transport of ions and solutes into the 
subretinal space.  A variety of transporter proteins are expressed in the RPE, 
including ion transporters, amino acid transporters and drug efflux pumps.  
Transporter proteins that expel solutes toward the choroid may decrease drug 
penetration to the retina.  Studies on the role of transporter proteins in ocular delivery 
have been very limited, and their level of involvement as transport barriers is largely 
unknown.  Michaelis-Menten kinetics predicts that at high drug concentrations, 
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transporter proteins will become saturated, reducing their effect.  However, since drug 
concentration levels at the RPE are typically low during transscleral delivery, 
transporter proteins may actually be a significant contributor as a barrier to the 
permeation of various drugs.  Many transporter proteins are receptors for specific 
compounds, and do not affect most other solutes.  While a short overview of 
transporter proteins in the RPE is presented below, a more exhaustive review on the 
transporters of the blood-retinal-barrier (BRB) including the RPE is given by 
Mannermaa et al [76]. 
 
 1.  Drug efflux pumps 
 Drug efflux pumps expel toxic and foreign molecules from the cell.  They 
consist of two major efflux transporters: P-glycoproteins (P-gp) and multidrug 
resistance-associated proteins (MRPs) [77].  Both pumps have a broad substrate 
specificity, with P-gp pumps generally expelling large neutral or cationic compounds 
and MRPs removing large neutral or anionic compounds [78].  P-gp and MRP 
expression have been reported in human RPE with efflux directed towards the 
choroid, [79-81] preventing drugs from entering the retina.   
 
 2.  Organic ion transporters 
 Many ophthalmic drugs are potential substrates of organic anion and cation 
transporters [76].  The active transport of organic anions by the RPE was first noted 
by Cunha-Vaz and Maurice [82].  Amines and various drugs exist as anions and 
cations at physiological pH.  Organic cation transporters (OCT) carry endogeneous 
 
 23 
 
amines such as choline, epinephrine, dopamine, guanidine, and histamine as well as 
organic cation drugs including anticholinergics, adrenergics, antihistamines, 
xenobiotics and vitamins [76].  Amino acid transporters for glutamate [83,84], taurine 
[85], and leucine [86] among others have been found in human RPE.  Many amino 
acids show a net flux from the retina to the choroid [87].  Solute transport may also be 
determined by the relative apical and basolateral concentrations of ions and solute, as 
in the case for taurine [88,89].  The anti-glaucoma drug brimodine has been shown to 
be a substrate of organic cation transporters, and its transport is dependent on 
extracellular pH, temperature, and concentration [90].  The organic anion-transporting 
polypeptide-E (OATP-E) has been found in the retina of rat eyes [91], but its 
localization is unknown.  Many transporter proteins require further investigation in 
vivo to accurately determine the direction of solute transport.   
 
1.3.3.  Metabolic Barriers 
 Since the eye is exposed to the atmosphere, it serves as a port of entry for 
xenobiotics into the body.  As a defense mechanism, the eye possesses metabolizing 
enzyme systems which degrade foreign substances that may cause harm to ocular 
tissues.  Drug metabolizing enzymes are present in many ocular tissues, but the 
ciliary body and the RPE are the most active sites of xenobiotic metabolism in the eye 
[92].  Higher levels of metabolic enzymes are required in these tissues since they are 
responsible for detoxifying drugs that are carried by the systemic blood circulation 
[93,94].  During transscleral delivery, the metabolizing enzymes of the RPE may 
degrade and detoxify drug molecules, limiting their transport to the retina.  Most 
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studies on metabolic enzymes have been focused on identifying and understanding 
the metabolic pathway, and there have been few reports that study their effect on 
ocular pharmacokinetics and distribution of drug molecules [95].  Therefore, the 
significance of metabolic barriers during transscleral delivery is currently not well 
understood.   
 While there are numerous metabolic enzyme systems in the eye, a brief 
description of major metabolic enzymes found in the RPE is given below.  More 
extensive reviews are given by Kumar [92] and Attar et al [78].     
 
1.3.3.1.  Cytochrome P-450 
 The enzymes of the cytochrome P-450 (CYP) family are the most important 
Phase I drug metabolizing enzymes [92].  Phase I enzymes introduce or unmask polar 
bodies through oxidation, reduction or hydrolysis reactions.  Sufficiently polar 
metabolites are then excreted while remaining products are further polarized by phase 
II enzymes such as acetyltransferase, sulfotransferase, and glutathione S-transferase 
[92].  High levels of CYP enzymes have been reported in mouse [96] and bovine RPE 
[93,97].  CYP enzymes have broad substrate specificity and metabolize endogeneous 
and xenobiotic compounds.  The CYP3A isozyme, for example, metabolizes more 
than 50% of commercial drugs [98].   
 
1.3.3.2.  Lysosomal enzymes 
 RPE cells play important roles in the formation of the blood-retinal barrier and 
in the regulation of solute transport and metabolism.  They are also responsible for 
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digesting shed photoreceptor outer segments which can cause degeneration of 
photoreceptor cells and subsequent loss of vision when allowed to accumulate.  RPE 
cells degrade the photoreceptor outer segments at a very high rate (3000 million disks 
in 70 years) [99], using various lysosomal enzymes.  Lysosomal enzymes, also 
known as acid hydrolases, are found in lysosomes and melanosomes [100] and can 
degrade proteins, polysaccharides, nucleic acids and lipids into low-molecular-weight 
constituents in an acidic environment [101].  Figure 1-10 shows the levels of 
lysosomal enzyme activity in ocular tissues compared to levels in the liver.  
Several ocular tissues express high levels of lysosomal enzyme activity.  In bovine 
ocular tissues, the highest levels of cathepsin B, cathepsin D and acid phosphatase are 
found in the RPE [101].  Other lysosomal enzymes including α-fucosidase, α-
mannosidase, and β-N-acetylglucosaminidase have also been reported in bovine RPE 
[102].  Natural macromolecular drugs as well as xenobiotics may be degraded by 
lysosomal enzymes during transport across the RPE, as they are able to cross 
lysosomal membranes by passive diffusion [103,104].   
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Figure  1-10.  Levels of lysosomal enzymes in ocular tissues. 
From reference [101]. 
 
 
1.3.4.  Concluding Remarks 
 Most studies on transport barriers affecting transscleral drug delivery have 
focused on the determination of permeability values of ocular tissues.  Permeability 
values are helpful for comparing diffusional resistances of one tissue to another and 
can also be used to calculate the diffusion coefficients of drugs.  However, 
permeability values or diffusion coefficients alone cannot be used to determine the 
transport of drugs in the eye, since dynamic and metabolic barriers can also affect 
drug distribution.         
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 The effect of dynamic barriers on drug penetration after transscleral delivery 
has been demonstrated in studies using magnetic resonance imaging (MRI), which 
allows the acquisition of three-dimensional images non-invasively in vivo.  Dynamic 
barriers are active in vivo but cease post mortem, while static barriers are always 
present.  A comparison of scans acquired in vivo and post mortem revealed increased 
penetration of a MRI tracer released from a polymeric episcleral implant into the 
anterior chamber and vitreous post mortem but not in vivo [105].  Similar results were 
obtained after subconjunctival injection of manganese ions [106].  The difference in 
results between the in vivo and post mortem scans suggest that dynamic barriers 
which cease post mortem significantly affect intraocular drug levels.  Therefore, 
assessment of transscleral drug penetration cannot be accurately determined in 
systems involving only static barriers.   
 While the general effect of dynamic barriers on transscleral drug delivery has 
been demonstrated, the effect of individual dynamic barriers is unknown.  The 
challenge of isolating the dynamic barriers during data acquisition currently prevents 
the direct comparison of one dynamic barrier to another.  Understanding the 
importance of individual dynamic barriers will enable the improved design of drug 
delivery methods and devices.  For example, the recent investigations examining the 
significance of conjunctival clearance has led to the design of the unidirectional 
episcleral exoplant [56], which minimizes drug loss to conjunctival blood and 
lymphatic flow.  The posterior infusion of drug into the suprachoroidal space [107] is 
another method to bypass the conjunctival clearance mechanisms, allowing for 
greater delivery of drug to the macula. 
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 A review of the literature shows that static barriers have been examined in 
detail, but studies investigating the significance of dynamic and metabolic barriers in 
transscleral drug delivery are sparse.  While tissue permeability is important for drug 
transport, recent in vivo studies demonstrate that clearance and elimination 
mechanisms play a significant role in reducing drug delivery to the retina.  Further 
studies exploring the effects of dynamic and metabolic barriers are warranted in order 
to improve our understanding of drug transport in transscleral delivery.    
 
1.4. Methods of Ocular Pharmacokinetic Data Measurement 
1.4.1. Traditional Methods 
Ocular pharmacokinetic data has typically been measured by administering 
the drug of interest in an animal model and enucleating the eye after a specified 
period of time.  The eye is then immediately frozen, the desired tissues dissected, and 
various extraction procedures are then performed to recover as much of the drug as 
possible.  However, this requires the use of several animals in order to monitor the 
change in drug levels over time.  Since there are physiological variations from one 
animal to the next, this adds error to the results and complicates pharmacokinetic 
analysis [108].  There are also errors in drug measurement as extraction efficiencies 
are often low and the thin, delicate tissues of the eye wall are difficult to completely 
isolate.     
Fluorescence, autoradiography and drug extraction from tissues are traditional 
ex vivo techniques used to study drug penetration and elimination in the eye [109-
112].  However, methods which require data measurement from tissues ex vivo may 
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not yield accurate results as the spatial distribution of drugs may change during the 
time interval that tissues are being harvested.  Additionally, tissues are usually 
digested in its entirety and one drug measurement is obtained for the entire tissue.  
Therefore, information regarding the distribution of drugs is lost.  Figure 1-11 shows 
a schematic which illustrates a sampling technique to acquire spatial drug distribution 
data; however, this technique is tedious and prolongs the dissection time.   
 
 
Figure  1-11.  Schematic of tissue sampling sites for ocular drug distribution 
assessment.  
From reference [113].   
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1.4.2. Non-invasive methods 
Owing to their non-invasiveness, imaging techniques have become attractive 
methods for the assessment of drug distribution [114-117] and drug delivery [118].  
Gamma scintigraphy, MRI, positron emission tomography (PET), and single photon 
emission computed tomography (SPECT) are some of the most widely used imaging 
modalities in studies of drug delivery and pharmacokinetics [114,116,119].  Nuclear 
imaging techniques (gamma scintigraphy, PET, and SPECT) have been widely used 
to assess the distribution of radiolabeled drugs in various applications such as in the 
determination of pharmacokinetics of anticancer therapies [120] and drugs for 
pulmonary delivery [121].  These methods also allow quantitation of drug distribution 
and drugs can be used as contrast agents after radiolabeling.  Several studies have 
successfully utilized fluorine-18-labeled ciprofloxacin for PET studies in humans 
[122,123].  They are highly sensitive methods, permitting drug concentration 
measurements as low as 10-12 mol/L [117].  The temporal and spatial resolution is 
also excellent, with typical image acquisition in seconds to minutes with 1-5 mm 
resolution [114].  However, the use of radioactive materials requires additional 
precautions to be taken during imaging procedures including radioactive waste 
handling and the radiation exposure of patients/volunteers and clinical staff.  Also, 
many radioactive tracers have short half-lives (15O, t1/2: 2.07 min; 13N, t1/2: 9.96 min; 
11C, t1/2: 20.4 min), limiting their use to short experiments [114]. 
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Optical coherence tomography (OCT) is another popular imaging method, 
with the most successful clinical application in ophthalmology [124,125].  OCT can 
achieve resolutions of 1-15 μm (10-100 times finer than MRI), and the imaging 
procedure can be carried out with noninvasive or minimally invasive delivery systems 
such as handheld probes, endoscopes, catheters, laparoscopes and needles [126].  
Despite the integration of OCT into various medical and biological applications, no 
optical contrast agents have been developed for this technology.  Since the image 
contrast mainly comes from the scattering and absorption of light by tissues, both the 
sensitivity and specificity of OCT have a strong dependence on the intrinsic optical 
properties of the biological sample, often limiting its diagnostic capability.   
MRI is a non-radioactive method which forms images from the nuclear 
magnetic resonance signal generated by certain nuclei (1H being the most commonly 
imaged) after being subject to a high magnetic field.  Typical sensitivity values range 
from 10-5 to 10-3 mol/L, the temporal resolution is on the order of minutes, and the 
anatomical resolution is higher than that of PET [117].  While high-resolution 
imaging of the eye has been reported in previous anatomical studies [127], the use of 
MRI for ocular pharmacokinetics has not been widely investigated.  In this research, 
ocular pharmacokinetic data was acquired by using dynamic contrast-enhanced 
magnetic resonance imaging (DCE-MRI).  Many MRI contrast agents are conjugates 
of gadolinium, a paramagnetic metal that increases the signal intensity of nearby 
water molecules in the presence of a magnetic field.  This allows the enhancement of 
contrast between tissues with and without contrast agent, and also increases the signal 
to noise ratio (SNR) of the image.  DCE-MRI permits the measurement of a magnetic 
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tracer by producing high-resolution images that can be obtained in real-time and non-
invasively in vivo.  DCE-MRI provides spatial and temporal measurements of drug 
levels in the eye, and may become an important tool in the study of ocular 
pharmacokinetics [128].   
In ocular research, DCE-MRI has become a valuable method in the study of 
the integrity and permeability of the blood-retinal barrier [129-131].  Ocular 
pharmacokinetic data have also been acquired with DCE-MRI by using a calibration 
curve to convert T1 or signal intensity values to the concentration of the contrast agent 
[105,132].  The increased utilization of non-invasive pharmacokinetic imaging tools 
such as DCE-MRI may enable better understanding of drug clearance and distribution 
in future drug delivery studies for the eye.   
 
1.5. Project Overview 
 As the development of ocular drug delivery devices has gained momentum in 
recent years, the gaps in the understanding of drug transport barriers in the eye have 
become more evident.  To address this need, pharmacokinetic imaging tools, more 
specifically MRI, have been proposed and recently utilized to assess drug delivery in 
the eye [105,106,133,134].  MRI is a versatile technique and can provide information 
that cannot be obtained from traditional invasive pharmacokinetic measurement 
methods.  No other quantitative technique has been explored for imaging the ocular 
distribution of drugs in vivo.  Therefore, the use of MRI is potentially very attractive 
and may play an important role in future studies of ocular drug delivery assessment.  
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However, as with any measurement technique, MRI has limitations which need to be 
investigated in order to ensure that the data is interpreted correctly.   
 To address the current needs of the ocular drug delivery community, several 
goals have been achieved in this work: (1) to evaluate transscleral drug delivery in 
vivo using MRI, (2) to assess MRI as a technique for evaluating drug delivery in the 
eye, and (3) to better understand the significance of individual barriers in the eye by 
quantitatively analyzing experimental (MRI) data and by pharmacokinetic modeling.  
Two major animal imaging projects are presented in this work: the assessment of 
sustained transscleral drug delivery by continuous infusion (Chapter 3) and the 
determination of drug elimination kinetics after subconjunctival injection (Chapter 4) 
using DCE-MRI.  These studies demonstrate the powerful potential of MRI and its 
advantages.  Chapter 2 discusses the method by which MR images are converted to 
quantitative results and the limitations in this conversion.  Chapter 5 presents a 
transscleral drug delivery model and the comparison of MRI data to the model results.  
Through this comparison, restrictions in the use of MRI for quantitative data 
measurement are discussed. 
 Since the initial stages of this research, there has been much interest in the 
ocular drug delivery community in the use of MRI for evaluating drug delivery.  The 
use of pharmacokinetic imaging tools such as MRI will likely continue to grow in 
ocular drug delivery.  Therefore, this work seeks to evaluate MRI as a 
pharmacokinetic imaging tool in ocular drug delivery, as well as present some of its 
powerful capabilities. 
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Chapter 2: Calibration of Contrast Agents 
  
2.1. Introduction 
2.1.1. MRI Physics 
 In nuclear magnetic resonance imaging, the signal is produced from the very 
center of the atom.  Atoms containing unpaired protons or neutrons have net spin and 
angular momentum.  All atomic nuclei with an unequal number of nucleons also 
possess a magnetic moment [135].  Figure 2-1 shows magnetic moments of atoms in 
random orientations.   
 
  
 
Figure 2-1.  Random alignment of atoms in the absence of an applied magnetic 
field.  
From reference [136]. 
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 When protons are exposed to the presence of a large external magnetic field 
(Bo), alignment of the magnetic moments occur either in the parallel (ground state, 
low energy) or antiparallel (excited state, high energy) direction (Fig. 2-2).  Slightly 
more protons are in the ground state, resulting in a net magnetization vector (Mo).   
 
 
Figure 2-2.  Alignment of atoms in the presence of an applied magnetic field Bo.  
From reference [136]. 
 
 
 
 In order to create an MR signal which can be detected, Mo must be reoriented 
into the transverse plane from the longitudinal axis to cause a signal in the 
radiofrequency (RF) receiver coils (Fig. 2-3).  A second magnetic field is applied in 
the form of a RF pulse to flip Mo into the transverse plane.  The frequency of the RF 
pulse is determined from the Larmor equation: 
 
0B×= γω       (1) 
 
 36 
 
  
where ω is the precessional frequency and γ is the gyromagnetic ratio (constant for a 
given nucleus; 42.58 MHz/T for hydrogen). 
 
 
 
Figure 2-3.  The longitudinal axis and the transverse plane.  
From reference [136]. 
 
 
 This energy applied in the form of a RF pulse is equivalent to the energy 
difference between the two proton states.  For a 1-T magnet system, the protons will 
resonate at 42.58 MHz.   
 MRI exploits frequencies in the radiowave range, as shown in Figure 2-4.  In 
this low frequency range, the human body is transparent to radiation which is low and 
nonionizing.   
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Figure 2-4.  The electromagnetic spectrum.  
From reference [136]. 
 
 
 Of all the atoms with unpaired nucleons, hydrogen is the most important atom 
for medical MRI since it makes up two-thirds of all atoms in humans.  Every cubic 
centimeter of water has approximately 1023 protons.  In addition to its chemical 
abundance in the body, hydrogen is also highly magnetic, increasing its MR 
sensitivity. 
 After the RF pulse is applied, signal will begin to immediately decay as 
protons lose coherence in precession.  There are two sources of irreversible signal 
loss: T1 and T2 relaxation.  The process of energy dissipation to the surrounding 
magnetic environment as protons move from the high excited energy state to the 
ground state is called T1 relaxation.  T1 is the time for 63% of the longitudinal 
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magnetization to recover following the RF pulse (Fig. 2-5).  The relationship of signal 
intensity (SI) and T1 depends on the time between RF pulses (repetition time or TR) 
and the T1 of the tissue [136]: 
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Figure 2-5.  The intensity curve for T1 relaxation.  
From reference [136]. 
 
 
 T2 is the loss of transverse magnetization and is the time necessary to reduce 
the transverse magnetization to 37% of its original value following the RF pulse (Fig. 
2-6).  The relationship between SI and T2 depends on the time from the RF pulse until 
the echo is received (echo time or TE) and the T2 of the tissue [136]: 
 
 
 39 
 
⎟
⎟
⎠
⎞
⎜
⎜
⎝
⎛
=
−
2T
TE
efSI       (3) 
 
 
 
Figure 2-6.  The intensity curve for T2 relaxation.  
From reference [136]. 
 
 
2.1.2. Pulse Sequence 
 As previously discussed, SI is produced by transverse magnetization, which is 
affected by T1 and T2 relaxation times.  Other factors also affect SI, such as proton 
density (N), flow (f[velocity]) as well as RF pulse characteristics.  While the specific 
equation for SI is dependent on the type of sequence used, a general form can be 
summarized as [136]: 
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 When a short TR and TE is used, the resulting image will emphasize the T1 
characteristics of the tissue, and is said to be “T1 weighted.”  A long TR and TE will 
result in a “T2 weighted” image.   
 
2.1.3. Contrast Agents 
 Paramagnetic materials are used to produce T1 shortening.  As seen from 
Figure 2-7, a decrease in T1 relaxation time results in increased signal intensity. 
Paramagnetic materials include metal ions that have unpaired electrons (such as 
gadolinium, iron, and manganese) which have unpaired spins.  The magnetic moment 
produced by these unpaired electrons is about 1000 times greater than that of a 
hydrogen nucleus [137].   
 Gadolinium-diethylenetriaminopentaacetic acid (Gd-DTPA, also known as 
Magnevist) is a paramagnetic agent, and develops a magnetic moment when placed in 
a magnetic field.  Gd-DTPA enhances the relaxation rate of water protons in its 
vicinity by decreasing the T1 relaxation time in tissues where it accumulates.  Gd-
DTPA is an extracellular contrast agent, and is cleared through the kidneys.  It is used 
widely clinically, and does not produce toxic effects in the body.  The DTPA chelate 
does not dissociate from the Gd ion, and overall the agent carries a -2 charge.  The 
agent is highly soluble in water.   
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 Other contrast agents such as Mn2+ and MnEDTA2- [106], MnCl2 [138], Gd-
albumin [139] have been explored in ocular in vivo studies as well as Gd-DTPA 
[105,131,134]. 
  
 
 
Figure 2-7.  The effect of T1 on signal intensity at a specified TR.  
From reference [136]. 
 
 
2.1.4. Factors Affecting MR Images 
 The signal-to-noise ratio (SNR) is an important factor in MR imaging.  Due to 
the low detection sensitivity of MRI, noise superimposed on the images can 
significantly degrade the image quality.  SNR can be most easily increased by 
increasing the voxel size or the number of excitations (NEX).   
 The voxel size is determined by the field of view (FOV), matrix size, and the 
slice thickness.  Increasing the voxel size increases the number of spins contributing 
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to the signal intensity, thereby increasing the SNR.  Therefore, increasing the FOV, 
decreasing the number of pixels in the FOV by decreasing the matrix size, and 
increasing the slice thickness will all contribute to increased SNR.  However, in doing 
this the spatial resolution will increase; therefore, a balance between spatial resolution 
and SNR must be achieved.  Increasing the FOV is particularly significant in 
ophthalmic MRI since the eye occupies a small area and spatial resolution can be 
quickly lost.  
 The SNR can also be improved at the expense of scan time by increasing the 
NEX.  However, increased scan times may not be permissible in studies where 
changes are occurring over short time periods.  Repeated sampling through increased 
NEX allows greater signal averaging.  The SNR increases proportionally with the 
square root of NEX, as shown in the following relation [140]: 
 
SNR ~ (FOV/matrix)*slice thickness*(NEX)1/2                     (5) 
 
 MRI is a multiparametric modality, and the trade-offs that accompany the 
choice of the operating parameters in terms of the achievable image contrast, spatial 
resolution, and scan time must be recognized [140].   
 
2.1.5. Conversion of Signal Intensity to Concentration 
MRI can be utilized as a quantitative technique by converting data from the 
acquired images into concentration values of drug in each pixel.  In order to convert 
image data into concentration levels of contrast agent, a calibration curve is needed.  
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The calibration curve is generated using various concentrations of contrast agent in a 
tissue phantom and scanning the samples using the same MR parameters that are used 
in the animal experiment.   
Different types of image data can be used to derive the concentration 
information of the contrast agent.  For example, if T1 scans are performed, various 
values of T1 can be measured at different known concentrations of contrast agent in 
tissue phantoms.  An example of a T1 calibration using the contrast agent MnEDTA2- 
is shown in Figure 2-2.   
 
 
Figure 2-8.  Calibration showing the linear relationship between inverse T1 
relaxation time and MnEDTA2- concentration.  
From reference [106]. 
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In this research, T1-weighted images were acquired, and signal intensity 
values (instead of T1 measurements) were used to calculate the concentration levels of 
contrast agent.  2% hydroxypropyl methylcellulose (HPMC) and phosphate buffered 
saline (PBS) were used as imaging phantoms.  As will be explained in Chapters 3 and 
4, 2% HPMC and PBS were chosen to mimic the suprachoroidal space and the 
subconjunctival bolus, respectively.   
 
2.2. Methods 
Tissue phantoms were prepared by using various concentrations of contrast 
agent (Gd-DTPA or gadolinium-albumin) in solutions of PBS (pH: 7.4) and 2% 
HPMC.  Gd-DTPA was purchased from Berlex, Inc. (Monteville, NJ) and 
gadolinium-albumin (Gd-albumin) was purchased from Biopal, Inc. (Galbuim; 
Worcester, MA).  HPMC was dissolved in PBS by stirring the solution at 90 ºC for 3 
hours.  Concentrations ranging from 10-6 to 0.5 M (stock concentration) for Gd-
DTPA and 10-6 to 0.37 mM (stock concentration) for Gd-albumin in either PBS or 
HPMC were poured into 2 mL HPLC glass vials to be scanned with MRI.  At least 4 
sets of each type of tissue phantom were prepared and imaged. 
 The calibration samples were placed within a volume coil, and MRI scans 
were acquired using the same sequence parameters used for the animal experiments.  
All MRI experiments were conducted using a 4.7 Tesla MRI system (Bruker 
Instruments, Billerica, MA).   
 Signal intensity values from images were determined using image analysis 
software, ImageJ (ver 1.33u, NIH, Bethesda, MD).  A circular region-of-interest 
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(ROI) was manually drawn inside each vial and the average signal intensity was 
measured.  Signal intensity values were normalized either to the signal intensity of the 
phantom without contrast agent (for Gd-DTPA samples in HPMC) or to the signal 
intensity of the administered concentration (1 mM for Gd-DTPA and 0.1 mM for Gd-
albumin in PBS) in animal experiments.  This data along with the corresponding 
concentration of contrast agent were used to generate the plot for the signal intensity 
vs. concentration calibration curve. 
 
2.3. Results 
Figure 2-9 shows an image from a calibration MRI scan using phantoms of 
Gd-DTPA in PBS in glass vials.  The varying signal intensity with concentration of 
contrast agent can be observed.   
 
 
Figure 2-9.  MR image of Gd-DTPA phantoms in PBS.  
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Figure 2-10 shows a calibration curve constructed for Gd-DTPA in PBS.  At 
low concentrations (<10-5 M), the signal intensity reaches a plateau and the limit of 
concentration detection is reached.  The signal intensity increases with Gd-DTPA 
concentration and a peak signal intensity is observed.  At high concentrations (>10-2 
M) the signal intensity decreases due to T2 shortening effects [141].   
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Figure 2-10.  Gd-DTPA calibration showing the relationship between 
concentration and signal intensity.  
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Figure 2-11 shows the calibration curve for Gd-DTPA in PBS utilized in MR 
image analysis for studies described in Chapter 4.  A sixth-order polynomial was fit 
to the selected data range to yield the best fit.  The calibration curve shows that the 
concentration detection range spans a couple orders of magnitude.  The limits of 
concentration detection are 3e-5 M and 0.05 M for Gd-DTPA in PBS.   
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Figure 2-11.  Gd-DTPA calibration in PBS.  
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Figure 2-12.  Gd-DTPA calibration in 2% HPMC.  
 
 
 Figure 2-12 shows the calibration of Gd-DTPA in 2% HPMC, with images 
acquired using the same MR parameters described in Chapter 3.  Signal intensity 
values are different at a given Gd-DTPA concentration when comparing Figures 2-12 
and 2-13 since the phantoms and MRI parameters (TR, TE) are different. 
 Figure 2-13 is the calibration used for Gd-albumin studies in Chapter 4.  The 
limits of detection are 0.005 to 0.37 mM.   
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Figure 2-13.  Gd-albumin calibration in PBS.  
 
 
2.4. Discussion 
Calibrations of various contrast agents in different phantom media can be 
constructed to quantitate MRI data.  While 2% HPMC has been used in prior studies 
to simulate tissues that contain loose connective tissue [105,134], it is more difficult 
to construct synthetic phantoms that will successfully mimic the relaxation rates in 
other ocular tissues that consist of more complex structures.   
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Table 2-1 gives a list of T1 relaxation rates from various ocular tissues 
determined in a rabbit eye.  These experimental T1 values are comparable to values 
reported for the human eye [142].  While the T1 of the vitreous is similar to the value 
for PBS and HPMC, the tissues such as the conjunctiva, choroid, and retina have 
extracellular volume fractions less than 50%, and have very different T1 relaxation 
rates than the tissue phantoms used in this study.  Therefore, phantom materials that 
have lower T1 relaxation rates should be used to construct calibrations for these 
ocular tissues, since the lower T1 value of the tissue will affect the T1 relaxation rate 
of contrast agent.   
 
Phantom/Tissue T1 (ms) 
PBS 3390 
2% HPMC 3201 
Conjunctiva 1701 
Sclera 1872 
Choroid-Retina 2288 
Vitreous 3307 
Table 2-1.  T1 measurements in phantoms and ocular tissues.  
 
 
There are currently no standards for use as tissue phantom standards in 
biomedical MR imaging (Workshop on Pharmacokinetic/Pharmacodynamic Imaging, 
USC, January 22-23, 2007).  All sectors in government, industry and academia realize 
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the important need for standardization in the use of tissue phantoms for accurate and 
consistent quantitative analysis in biomedical imaging.  Agarose is typically used as a 
brain tissue phantom, but this may not be a good phantom for ocular tissues since 
tissue compositions vary.   
The concentration range detected by using signal intensity data spans about 2-
3 log units.  This range may be further increased by using T1 measurements instead of 
signal intensity data.  While sensitivity may be increased by using T1, longer scan 
times are required to acquire T1 scans (~1 hour for one scan).  For the studies in this 
research, short scans (~3-11 minutes) were required to capture the kinetic changes 
that were occurring in ocular tissues.  Therefore, performing T1 scans was not feasible 
in this study, but may be used in other experiments that can accommodate longer scan 
times.   
 
2.5. Conclusion 
 The results from scanning MRI phantoms show that there is a concentration 
range that may limit the measurement capability for certain experiments.  The 
phantoms used in this study cannot be used for cellular tissues, since there is a large 
discrepancy in T1 relaxation rate.  While limitations in conversion may exist, MRI is 
highly advantageous in acquiring tissue concentration levels in vivo which is not 
feasible with many traditional ocular pharmacokinetic measurement techniques.   
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Chapter 3: Assessment of Sustained Drug Delivery by Infusion 
3.1. Introduction 
 Due to the lack of clinical efficacy in transscleral drug delivery, the 
incorporation of sustained release methods have been proposed to enhance delivery to 
the choroid and retina [3,25].  As previously discussed in Chapter 1, sustained 
delivery methods include the use of micro and nanoparticles and polymeric implants 
loaded with drug.  Recently, transscleral delivery methods involving continuous 
infusions have been reported using an osmotic pump for sustained delivery into the 
eye [20,21].  Figure 3-1 is an illustration from a study in which an osmotic pump 
attached to a flexible catheter was inserted into the sclera for continuous drug 
delivery.  The study concluded that bioactive proteins infused in this manner 
delivered therapeutic levels to the choroid and retina with negligible systemic 
absorption.   
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Figure 3-1.  Intrascleral osmotic pump implantation in a rabbit eye.   
From reference [20]. 
 
  
 In this study, sustained transscleral drug delivery was explored by continuous 
infusionin the live rabbit.  Two different transscleral infusion methods were 
investigated by positioning the catheter either subconjunctivally or intrasclerally.  
Magnetic resonance imaging was utilized to evaluate delivery and its capability in 
imaging drug delivery in the eye was also assessed. 
 
3.2. Methods 
3.2.1. Animal Setup 
 Female New Zealand White rabbits weighing 3-3.5 kg were purchased from 
Covance Laboratories, Inc. (Vienna, VA, USA) and were used according to the 
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guidelines set forth in the ARVO statement for the Use of Animals in Ophthalmic and 
Vision Research.  Rabbits were monitored under general anesthesia during the MRI 
scan period.  Placement of subconjunctival catheters behind the globe has been 
previously reported to deliver drugs to the macular region [20,143].  However, access 
to the back of the globe is difficult and intrascleral catheter placement may result in 
an inadvertent perforation.  As a result, we placed catheters anteriorly, with the axis 
parallel to the limbus, for easier access.  A 9-0 vicryl suture was placed at the limbus 
and the eye was rotated downward to expose the superonasal quadrant.  A 24 gauge × 
¾ inch long intravenous catheter (Terumo Medical Corporation, Somerset, NJ) was 
prepared by removing the plastic tubing and hub from the needle and cutting off the 
tubing from the hub (Fig. 3-2).  The tube and hub were threaded back onto the needle 
and then inserted either subconjunctival or intrascleral 3-4 mm from the limbus.  For 
intrascleral insertions incisions were made in the conjunctiva and Tenon’s fascia with 
Wescott scissors to reveal bare sclera to ensure that the tubing was placed intrascleral.   
The catheter was inserted superonasally and was advanced into the eye at least 5 mm 
for subconjunctival infusions and 3 mm for intrascleral infusions.  The needle was 
then carefully withdrawn, leaving the catheter remaining in the tissue.  The eyelids 
were sutured closed to prevent corneal and sclera desiccation during the scan, and the 
distal portion of the catheter was left protruding out between the eyelids.  The 
catheter was connected to 7 m of PE-10 tubing (Becton Dickinson, Franklin Lakes, 
NJ) by a 10 cm length of silicone tubing (0.025” ID × 0.047” OD RenaSil; Braintree 
Scientific, Inc., Braintree, MA).  The silicone tubing was glued on one end to the PE-
10 tubing and prefilled with Gd-DTPA solution before connecting to the catheter by a 
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friction fit.  The Gd-DTPA solution was prepared by diluting the stock concentration 
100-fold in PBS (pH 7.4) to 5 mM.  The solution was administered through the entire 
tubing by using a programmable infusion syringe pump (Stoelting Co., Wood Dale, 
IL) located outside the scan room.  A 3-way stopcock was used to connect the syringe 
and the PE-10 tubing to prevent leakage of solution from the catheter before and after 
the infusion.  The Gd-DTPA solution was faintly colored with 100 mg/ml sodium 
fluorescein (Akorn, Inc., Decatur, IL) to a final concentration of 0.5 mg/ml to 
enhance visibility of the fluid in the tubing.   
 
 
 
Figure 3-2.  Photograph of IV catheter.   
24 gauge IV catheter shown with plastic hub and tube removed from needle.  Arrow 
indicates point of separation of plastic hub and tube. 
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Figure 3-3.  Custom-built surface coil placed over the rabbit eye.   
 
 
 3.2.2. MRI Setup 
 Experiments were performed using a 4.7 Tesla MRI system (Bruker 
Instruments, Billerica, MA).  Following placement of the catheter, a 4 cm passively 
decoupled receive-only surface coil was placed over the rabbit’s eye (Fig. 3-3).  The 
rabbit was placed on a cradle and inserted in a transmit-only volume coil.  T1-
weighted images were acquired using a 2D spin echo sequence.  The sequence 
parameters were: TR/TE = 400/16 ms, FOV = 4.7 × 4.7 cm2, matrix = 256 × 256, and 
averages = 2.  Each scan lasted 3.5 minutes.  Three contiguous 1.5 mm slices were 
acquired using two different orientations (Fig. 3-4).  Slices in orientation 1 (O1) were 
aligned parallel to the cornea and placed near the posterior edge of the lens.  Slices in 
orientation 2 (O2) were orthogonal to O1 and cut through the major axis and the 
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infusion site.  One set of scans (O1 and O2) was acquired before the start of infusion.  
The infusion was then started at either 1 or 10 µl/min, and the eye was scanned 
continuously for 20-30 minutes.  For rabbits infused intrascleral, the infusion was 
then halted and scanning continued until Gd-DTPA signal had cleared completely 
from the suprachoroidal space.  All rabbits were euthanized by pentobarbital overdose 
(200-250 mg/kg) at the end of each MRI experiment.  All experiments were repeated 
at least in duplicate. 
 
 
 
Figure 3-4.  Positioning of slices in O1 and O2 shown on a schematic eye.   
Slices in both O1 and O2 intersect the site of infusion (shaded circle in gray).  
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3.2.3. Image Analysis 
MR images were analyzed using ImageJ.  Signal intensities from MR images 
were normalized to an average signal intensity from a region-of-interest (ROI) 
determined within the vitreous for each scan.  We assumed that the concentration of 
Gd-DTPA within the vitreous was negligible during the time course of all 
experiments.  Temporal analysis of the signal intensities from the vitreous region 
starting from the pre-injection scan to the end of the experiment indicated that its 
signal intensity value was relatively constant with values that were 5 to 10 times 
lower than the average signal intensity values from the suprachoroidal region.  The 
signal intensities in the vitreous had a mean fluctuation of ±15% during the entire 
course of each experiment.  Further support for the assumption of negligible vitreous 
concentration is derived on the basis of the low Gd-DTPA permeability of the ocular 
tissues (See Discussion). 
To perform quantitative calculations of clearance rates for Gd-DTPA 
clearance from the suprachoriodal space, the normalized signal intensities for each 
pixel in an ROI were recorded and converted into Gd-DTPA concentration by using a 
calibration curve determined from various concentrations of Gd-DTPA in 2% HPMC 
samples in PBS (Fig. 2-12).  The calibration curve was constructed by scanning the 
HPMC samples with the same MR imaging parameters used for the rabbit infusion 
experiments.  The peak signal intensity of the calibration curve occurred at 5 mM, 
which was chosen as the infusion concentration.  A similar calibration curve has been 
previously reported [58].  The lower detection limit of this technique was 0.1 mM. 
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The circumferential distribution and clearance rate of Gd-DTPA in the 
suprachoroidal space was determined from the 3 image slices acquired in O2 during 
intrascleral infusion experiments.  The mass clearance rate of Gd-DTPA from the 
suprachoroidal space was calculated from the normalized signal intensity converted to 
concentration in each image by the following procedure: an ROI was established in 
each of the 3 slices from the last scan obtained before halting infusion to monitor the 
clearance of Gd-DTPA from the suprachoroidal space.  The ROI consisted of a 
curved line that was drawn through the hyperintense suprachoroidal band.  The ROIs 
were saved and superimposed onto the images of successive scans acquired during 
Gd-DTPA clearance.  Normalized signal intensities for each pixel in an ROI were 
recorded and pixels with values near background intensity were discarded.  The 
remaining pixels of the ROI were used to calculate a mean signal intensity which was 
converted into the average Gd-DTPA concentration of the suprachoroidal space.   
 The mass of Gd-DTPA for each image was determined by multiplying the 
average concentration of Gd-DTPA by the volume of the corresponding 
suprachoroidal space (number of pixels remaining in the ROI × pixel volume).  The 
average mass of Gd-DTPA in the suprachoroidal space was computed using the mass 
values of the 3 slices.  The average mass clearance of Gd-DTPA was fit to an 
exponential function, M=Ae-kt, where M is the mass of Gd-DTPA in the ROI at time 
t, A is a constant, and k is the rate constant for clearance.  The half-life was derived 
from the rate constant (t1/2 = 0.693/k).  Regressions were also performed on semi-log 
plots of M vs. time and P-values of the goodness-of-fit of the exponential curve were 
computed. 
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3.2.4. Histology Study    
Six rabbits were infused at 10 µl/min intrascleral under anesthesia with 5 mM 
Gd-DTPA for 1 hour to examine the eye histologically for toxicity.  Two rabbits were 
euthanized and the infused eyes enucleated immediately upon death.  The four 
remaining rabbits were recovered from anesthesia, and two rabbits were enucleated 
after 24 hours and the remaining two after 3 weeks.  To limit the potential for fixation 
artifacts and to maintain the spatial relationship of the choroid and retina, enucleated 
eyes were immediately placed in plastic molds filled with embedding medium 
(Tissue-Tek O.C.T. Compound, Sakura Finetek, Torrance, CA, USA) and flash 
frozen at -80˚C.  Frozen eyes were sectioned coronally at 10 µm slices on a cryostat 
at -20˚C and fixed in 4% paraformaldehyde after sectioning.  Dried sections were 
stained with hematoxylin-eosin for light microscopy.  Histological sections were also 
acquired from rabbits without prior infusion to serve as control images. 
 
3.3. Results 
Figure 3-5 shows an MR image acquired before infusion of Gd-DTPA.  Many 
ocular structures can be delineated, including the layers of the cornea and defined 
structures of the ciliary body, lens and optic nerve.  The conjunctiva, sclera and 
choroid/retina can also be identified, particularly in Figure 3-6D, as the conjunctiva 
and choroid/retina appear hyperintense and the sclera appears hypointense in a T1 
weighted image [142].   
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3.3.1. Subconjunctival Infusion 
Most of the Gd-DTPA infused subconjunctival appeared to remain in the bleb 
formed by the conjunctival tissue (Fig. 3-6B and C).  Increasing the infusion rate 
from 1 to 10 µl/min only increased the bleb size and did not contribute to any 
noticeable penetration of Gd-DTPA into the underlying tissues.  Additional 
experiments were performed with 10 µl/min subconjunctival infusions lasting up to 2 
hours (data not shown).  However, a comparison of the scans to those acquired before 
infusion revealed that levels of Gd-DTPA were below the detection limit in the 
choroid/retina during the entire scan period.     
 
 
Figure 3-5.  T1 weighted MR image of the eye in O2 before infusion.  
a: cornea, b: ciliary body, c: lens, d: optic nerve 
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Figure 3-6.  MR images of subconjunctival vs. intrascleral infusion. 
After 42 minutes of subconjunctival infusion (A) at 1 µl/min and (B) at 10 µl/min.  
After 31.5 minutes of intrascleral infusion (C) at 1 µl/min and (D) at 10 µl/min.  
Arrows: catheter tubing; arrowheads: Gd-DTPA in suprachoroidal space.  The color 
scale bar on the left indicates the signal intensity converted to concentration in Molar 
units. 
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3.3.2. Intrascleral Infusion 
During intrascleral infusions, Gd-DTPA was seen to appear in the 
suprachoroidal space, indicated by the inner hyperintense band (Fig. 3-6C, D).  Due 
to limited resolution, the distribution of Gd-DTPA in the inner choroid and retina was 
not discriminated.  There was no Gd-DTPA detected in the anterior chamber with a 
small increase in signal intensity present in the ciliary body region near the catheter 
tip. 
 Gd-DTPA was detected in the suprachoroid immediately after the start of 
infusion at 1 and 10 µl/min.  Gd-DTPA began to spread posteriorly in the 
suprachoroid from the infusion site.  Figure 3-7 represents the distance traveled from 
the infusion site by the leading edge of the Gd-DTPA signal.  After 7 minutes of 1 
µl/min infusion, the posterior spread of Gd-DTPA in the suprachoroid reached a 
steady state and covered an average circumferential distance of 7 mm (Fig. 3-7).  
Prolonged infusion produced only a minimal increase in Gd-DTPA distribution.  
Figure 3-8 shows the spread of the Gd-DTPA signal in the O1 and O2 planes during a 
10 ul/min intrascleral infusion.  Increasing the infusion rate to10 µl/min caused Gd-
DTPA to travel farther in the suprachoroidal space.  This distance is shown in Figure 
3-7 (squares).  After 14 minutes of infusion Gd-DTPA had reached the optic nerve 
(Fig. 3-8F).  Continued infusion increased the amount of Gd-DTPA in the 
suprachoroidal space.  Gd-DTPA was also detected in the conjunctiva near the 
infusion site.  This suggests that intrascleral catheters may also allow Gd-DTPA to 
partially infuse into the overlying conjunctiva. 
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  A comparison of images taken in O1 (Fig. 3-8 A through D) and O2 (Fig. 3-8 
E through H) show that Gd-DTPA is able to travel slightly farther by moving parallel 
to the limbus rather than in the posterior direction towards the optic nerve.  This may 
be due to the transport and mechanical properties of the involved tissues but could 
also be influenced by the orientation of the catheter, which was placed parallel to the 
limbus rather than pointing towards the posterior pole of the eye.   
 
 
 
Figure 3-7.  Spread of Gd-DTPA measured in the suprachoroidal space.  
Measurements taken from images in O2 during intrascleral infusion at 1 µl/min 
(triangles) and 10 µl/min (squares).   
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Figure 3-8.  Time series MR images during intrascleral infusion.   
Images acquired with O1 (A-D) and O2 (E-H) during 10 ul/min intrascleral infusion.  
Images in O1 after infusing for (A) 3.5 minutes, (B) 10.5 minutes, (C) 17.5 minutes, 
(D) 24.5 minutes.  Images in O2 after infusing for (E) 7 minutes, (F) 14 minutes, (G) 
21 minutes, (H) 28 minutes.  Arrows indicate approximate location of catheter. 
 
 
3.3.3. Suprachoroidal Clearance   
 Qualitatively, the MR images in Figure 3-9 show that the concentration of Gd-
DTPA in the suprachoroidal space decreases uniformly after halting intrascleral 
infusion.  Images shown in Figure 3-9 were positioned more obliquely than images 
shown in Fig. 3-8 E through H. 
 The clearance rate of Gd-DTPA from the suprachoroidal space was 
determined from a quantitative analysis of Gd-DTPA mass at sequential time points 
as described in the Methods.  The rates of suprachoroidal clearance for 1 µl/min and 
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10 µl/min infusions are plotted in Figure 3-10 using the average mass from the 3 
slices acquired in O2 for each scan.  The clearance data shows a good fit to 
exponential equations (P-values in Figure 3-10 caption).  This suggests that the mass 
clearance from the suprachoroidal space can be modeled as first-order for both 1 and 
10 µl/min infusions, with half-lives of 5.4 and 11.8 minutes, respectively.   Complete 
Gd-DTPA clearance from the suprachoroidal space after intrascleral infusion at 1 and 
10 µl/min required approximately 20 and 60 minutes, respectively.  
 
 
 
 
Figure 3-9.  Time series MR images of suprachoroidal clearance.   
(A) After intrascleral infusion for 23 minutes at 10 µl/min.  After halting infusion for 
(B) 21 minutes and (C) 63 minutes. 
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Figure 3-10.  Suprachoroidal clearance after 1 and 10 µl/min intrascleral 
infusion.   
Data points are mean ± SD of 3 slices.  Triangles: rabbit 1; squares: rabbit 2.  Open: 1 
µl/min; filled: 10 µl/min.  Dashed lines: exponential curve fit for rabbit 1; solid: 
rabbit 2.  Average half-life: 5.4 min (1 µl/min), 11.8 min (10 µl/min).  The goodness-
of-fit P-values for all experiments were <0.0001 except for rabbit 1, 1 µl/min which 
was 0.001.   
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3.3.4. Histological Examination   
 Eyes enucleated immediately after 1 hour of 10 µl/min intrascleral infusion 
showed an expansion of the suprachoroidal space (Fig. 3-11).  This indicated that 
much of the infused Gd-DTPA solution accumulated in the suprachoroidal space.  In 
eyes enucleated 24 hours after infusion, the suprachoroidal space had normalized and 
tissue structures were no different from control images taken before infusion (Fig. 3-
11A).  Eyes enucleated 3 weeks after infusion also showed normal ocular tissues by 
light microscopy.  
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Figure 3-11.  Histological images of the suprachoroidal space.   
Hematoxylin-eosin stained light microscopy images.  (A) Without infusion, (B) after 
10 µl/min infusion for 1 hour.  Scale bar represents 50 µm. 
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3.4. Discussion 
3.4.1. Assessment of Sustained Drug Delivery by Continuous Infusion    
Subconjunctival sustained infusions demonstrated no detectable levels of Gd-
DTPA in the choroid/retina using dynamic MRI, possibly because of clearance by 
conjunctival blood vessels and lymphatics [52,105] and by rapid removal of any 
agent that does diffuse to the choroid.  The results from this study show that the 
concentration of Gd-DTPA in the choroid/retina was under the MRI detection limit 
after sustained subconjunctival delivery by continuous infusion. 
In contrast, intrascleral infusions expanded the suprachoroidal layer and 
rapidly delivered Gd-DTPA circumferentially and posteriorly with very limited 
anterior segment exposure.  Our results indicate that higher infusion rates allow 
greater distribution of Gd-DTPA in the suprachoroidal space.  While intrascleral 
infusions of 10 μl/min achieved Gd-DTPA delivery to the optic nerve after 15 
minutes, infusions of 1 μl/min localized the spread of Gd-DTPA near the infusion 
site.  The rate of infusion and clearance may have reached equilibrium during 1 
μl/min infusions, and this may account for the steady state in spatial distribution of 
Gd-DTPA in the suprachoroidal space.  
The suprachoroidal space is a virtual space and is avascular, consisting of 
loose connective tissue [63,144].  It was assumed that after intrascleral infusion the 
suprachoroidal space consisted mostly of Gd-DTPA solution (as shown by histology), 
and that this could be adequately modeled using a polymer solution.  Gd-DTPA 
calibrations were not made for other ocular tissues (sclera, choroid, retina), since 
 
 71 
 
quantitative calculations were only performed for the Gd-DTPA signal present in the 
suprachoroidal space.  
 
3.4.2. Assessment of Suprachoroidal Delivery    
Although the suprachoroidal clearance data from this study was obtained from 
a portion of the globe, an estimate of the amount of Gd-DTPA present in the entire 
suprachoroidal space after 30 minutes of infusion at 10 μl/min can be calculated by 
multiplying the average suprachoroidal Gd-DTPA concentration by the volume of the 
suprachoroidal space.  Adapting a methodology for the calculation of the scleral 
surface area [145], the surface area of the suprachoroid was approximated as 8 cm2.  
The suprachoroidal space is included within a volume of 8 cm2 multiplied by the 
pixel width (0.184 mm).  This yields an approximate apparent volume of 150 mm3.  
Since the average concentration of Gd-DTPA after 30 minutes of infusion is about 
0.001 M, the estimated mass of Gd-DTPA in the suprachoroidal space is 
approximately 0.14 mg.  This value represents about 10 % of the total infused amount 
of Gd-DTPA.   
Suprachoroidal clearance of Gd-DTPA was rapid, and the agent was 
undetectable in the eye after about 1 hour following a 10 µl/min infusion.  Clearance 
of Gd-DTPA followed first-order kinetics and the average half-life after a 30-minute 
10 μl/min infusion was approximately double that of a 1 μl/min infusion.  Although 
the higher infusion rate increased the half-life, the fast elimination of Gd-DTPA from 
the suprachoroidal space suggests that infusions may need to be maintained for a 
defined time period to successfully deliver desired amounts.  The actual mechanisms 
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responsible for the decrease of Gd-DTPA are not known but could include diffusion 
and convection through the sclera [64,65], uptake by the choriocapillaris [146], and 
movement of tracer laterally out of the plane of the image slices.  The pressure 
created by the solution infused into the eye may also contribute to the elimination of 
Gd-DTPA.   
In calculating the suprachoroidal mass clearance of Gd-DTPA, the number of 
pixels in the ROI that were above background signal intensity decreased with time, 
and this may reflect the volume decrease of the suprachoroidal space after halting 
infusion.  While the data from this study is insufficient to determine if the decrease in 
Gd-DTPA mass is due to the decrease in volume, the normalization of the 
suprachoroidal space over time indicates that fluid may also be cleared from the 
suprachoroidal layer.       
The expansible capabilities of the suprachoroidal layer have been 
demonstrated clinically where large choroidal effusions following glaucoma filtering 
procedures can resolve without sequelae [147].  Previous animal studies with 
deliberate expansion of the suprachoroidal space with volumes of hyaluronate > 300 
µl show complete resolution without toxicities [148,149].  Our histological studies 
with rabbits that were infused intrascleral at 10 µl/min for 1 hour showed that the 
suprachoroidal layer could expand and contract without affecting tissue morphology 
and structure.  This suggests that intrascleral infusions at rates of up to 10 µl/min for 
1 hour can be safely performed in rabbits.  
Technological advances with programmable implantable pumps across many 
specialties can potentially be applied to deliver drugs in the sclera for an extended 
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period of time [150-152].  Since there are no implantable infusion pumps approved 
for ocular drug delivery, a 15-minute intrascleral infusion using an external pump 
may be feasible to deliver a sustained-release formulation into the suprachoroidal 
space over the macular region [153,154].  The suprachoroidal space would serve as a 
reservoir for a sustained-release formulation that establishes a steep concentration 
gradient for drug diffusion into the choroid and retina.  Investigators have directly 
accessed the posterior segment through the suprachoroidal space using either a rigid 
[153] or flexible cannula [154].  Following placement of a cannula behind the porcine 
eye via the suprachoroidal space and injection of a triamcinolone acetonide depot 
posteriorly, pharmacokinetic studies showed high local drug concentrations in the 
choroid and retina in the macular region for at least 4 months [154].  The flow-
assisted delivery system used in our study may be a safer alternative since mechanical 
damage from the catheter tip, such as choroidal tears and optic nerve injury, would be 
avoided [154].  Diffusion-based implants have also been used for drug delivery to the 
retina through the suprachoroidal space requiring surgical incisions for placement of 
the implant [19,155].  However, the implant insertions, requiring incisions through 
the sclera and dissection to the suprachoroidal space, are invasive and may have a 
greater potential for adverse events. 
 
3.4.3. Advantages and Limitations in using MRI for Drug Delivery Assessment    
In this study we used a custom-built surface coil to acquire high resolution 
scans of the eye.  The surface coil localizes the magnetic field to a smaller region and 
permits higher spatial resolution.  An in-plane resolution of 0.184 × 0.184 mm was 
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achieved, which was sufficient to delineate several tissues comprising the eye wall.  
Higher resolutions have been reported in ophthalmic MRI [156], but were unable to 
utilize these scanning methods in this study due to limitations in temporal resolution.  
As described in Chapter 2, there is always a compromise between spatial and 
temporal resolution, and higher resolutions may be achievable in measuring processes 
with slower dynamics.   
To achieve high resolution, we were only able to scan a portion of the orbit (3 
contiguous slices), and a 3-dimensional scan could not be achieved in our desired 
time frame.  For this particular study, assessment of drug delivery was feasible by 
analyzing 2D slices, since a major goal was to visualize the posterior distribution of 
drug by infusional delivery.  Depending on the desired outcome measurements, 
however, a 2D imaging technique may not always suffice, and spatial and temporal 
resolution may have to be sacrificed in order to achieve 3D imaging. 
Despite the high resolution we were able to achieve with the surface coil, 
there were still limitations in sensitivity and resolution which prevented the detection 
of low levels of Gd-DTPA in the choroid/retina and vitreous and the delineation of 
the plane between the neurosensory retina and choroid.  The spatial resolution used in 
this study also could not clearly separate the Gd-DTPA solution filled suprachoroidal 
space from the choroid/retina.  Partial volume averaging may contribute to error in 
calculation of the Gd-DTPA mass clearance rate.  The dynamics of suprachoroidal 
Gd-DTPA distribution during and after infusion are rapid, and fast scan times were 
necessary to acquire a sufficient number of images for clearance rate determination.   
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In addition to the MRI issues of spatial and temporal resolution, there were 
several other limitations in this study.  One has to be cautious in extrapolating ocular 
imaging data from rabbit to human given the relative differences in the size of the 
eye, scleral thickness, choroidal flow velocities, and degree of retinal vascularization 
[157-159].  In addition, the results of the ocular distribution and clearance of Gd-
DTPA cannot be generalized to all drugs because of differences in properties relevant 
to drug transport [3,20,41,143].  The effect of pigment binding in the uvea can 
influence drug transport, but this is not studied appropriately in albino rabbits.   
In this study, the concentration of Gd-DTPA in the vitreous was assumed to 
be below the detection limit of 0.1 mM at all times for all experiments.  We 
normalized all signal intensity values to the vitreous signal intensity which we 
assumed to have negligible concentrations Gd-DTPA.   We feel that this assumption 
is justified on the basis of the low infusion concentration (5 mM), the limited time 
course of our image acquisitions, and low the permeability of the retina-choroid-
sclera membrane (2.0 × 10-6 cm/sec) [58] to Gd-DTPA.  Using higher concentrations 
of Gd-DTPA may produce lower signal intensities near the infusion site due to T2 
shortening effects, but the concentration of Gd-DTPA in the vitreous may rise above 
detection limits and allow measurement of Gd-DTPA concentration levels.  As 
previously mentioned in the Methods, the average signal intensity of the vitreous did 
not significantly change during the duration of the experiments of our study.  Longer 
scan times may allow greater amounts of Gd-DTPA to accumulate in the vitreous, 
producing higher signal intensities.      
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DCE-MRI has been shown to be useful in determining pharmacokinetic and 
physiologic properties [160,161].  Studies involving ocular pharmacokinetics with 
MRI have been previously reported [132,162,163].  MRI pharmacokinetics is an 
emerging field [160,164] and the improved resolution with newer generation scanners 
[165] will allow for non-invasive pharmacokinetic analysis in pre-clinical evaluation 
of ocular drug delivery systems. 
 
3.5. Conclusion 
 An intrascleral continuous infusion was successful in transporting Gd-DTPA 
to the posterior segment from an anterior infusion site with limited anterior segment 
exposure.  The suprachoroidal space appears to be an expansible conduit for drug 
transport to the posterior segment and may be able to deliver drugs to the macular 
region.     
 The results from this study also demonstrate the advantages and limitations in 
the DCE-MRI technique.  While a surface coil was used to improve resolution, only a 
portion of the globe could be scanned since a 3D scan could not be completed within 
the desired time frame.  However, the use of the surface coil produces high resolution 
images of the eye, and the conjunctiva, sclera and choroid/retina can be clearly 
delineated.  A 2D scanning technique utilizing a surface coil designed for optimal 
imaging of the eye can be useful in assessing drug delivery techniques in which high 
spatial resolution is crucial for outcome measurement.   
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Chapter 4: Drug Elimination Kinetics after Subconjunctival 
Injection  
 
 
4.1. Introduction 
As discussed in Chapter 1, subconjunctival injections are one form of 
transscleral drug delivery.  Subconjunctival injections are routinely performed in 
patients to administer drugs such as corticosteroids [166] and antibiotics [167] for 
ocular treatment.  Drug solutions injected into the subconjunctival space form a 
localized depot, which may allow for long-term sustained delivery.  After 
subconjunctival injection, drugs penetrate the eye directly through the underlying 
tissues [111] and therapeutic concentrations can be achieved in the vitreous [168].  
While subconjunctival injections are commonly performed, the retention time of drug 
and the rate of drug elimination from the depot are unknown and have not been 
investigated in detail.   
Previous methods of examining the change in drug levels in the 
subconjunctival space after injection include extracting drug from the excised depot 
[169] and using a scintillation counter to measure the rate of loss of gamma-emitting 
materials [170].  Drug extractions are inefficient since they require the use of multiple 
animals and it is also difficult to successfully remove the entire depot for analysis.  
The measurement of gamma-emitting compounds can give quantitative results in vivo 
but lacks information on spatial distribution.  Magnetic resonance imaging has 
recently been introduced as a non-invasive approach to assess the subconjunctival 
delivery of ionic permeants [106].  The study by Li et al analyzed concentration 
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levels of Mn2+ and MnEDTA2- in the anterior chamber, posterior chamber, and the 
vitreous to assess the permeation and clearance of model ionic permeants.  In our 
study, we measured the concentration levels of model drugs injected into the 
subconjunctival space using three-dimensional DCE-MRI.  The rate of drug clearance 
was determined by following the concentration changes of the injected contrast agent 
from the local depot.     
Recent studies have demonstrated that elimination mechanisms present in vivo 
such as conjunctival lymphatic clearance and blood flow can significantly reduce the 
penetration of drugs to the vitreous [105] and anterior chamber [106] after transscleral 
delivery.  The effect of dynamic clearance mechanisms on drug concentration levels 
in the subconjunctival space was studied by performing experiments in vivo and post 
mortem.  Two different contrast agents, Gd-DTPA (590 Da) and Gd-albumin (67.5 
kDa), were used as model drugs to understand the effect of molecular weight on 
clearance rate.  The effect of injection volume was also studied by administering 
different volumes (60, 200, and 600 µl) of Gd-DTPA. 
 
4.2. Methods 
4.2.1. Animal Setup 
Female New Zealand White rabbits weighing 3-3.5 kg were monitored under 
general anesthesia during the entire MRI scan period.  Proparacaine 1% ophthalmic 
drops (Allergan America, Hormigueros, PR) were used topically on the eye.  The 
superotemporal quadrant was exposed by placing a 9-0 vicryl suture at the limbus and 
rotating the eye downward.  A 24 gauge × ¾ inch long intravenous catheter was 
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prepared as described in Chapter 3.  The catheter was then inserted through the eyelid 
and advanced at least 5 mm superonasally under the conjunctiva.  The needle was 
carefully withdrawn, leaving the tip of the catheter under conjunctival tissue (Fig. 4-
1).  The catheter was held in place by the puncture through the eyelid.  The eyelids 
were closed with tissue adhesive (Vetbond, 3M Animal Care Products, St. Paul, MN) 
and the tip of the catheter was connected to 7 m of PE-10 tubing by a 10 cm length of 
silicone tubing (0.025” ID × 0.047” OD).  The silicone tubing was glued on one end 
to the PE-10 tubing and prefilled with contrast solution before connecting to the 
catheter by a friction fit.  The tubing was prefilled with either Gd-DTPA diluted to 1 
mM in PBS or Gd-albumin diluted to 0.1 mM protein in PBS before connecting to the 
catheter.  The contrast solution was faintly colored with 100 mg/mL sodium 
fluorescein to a final concentration of 0.5 mg/mL to enhance visibility of the fluid in 
the tubing.  The bolus was administered after the rabbit was placed into the magnet 
and preliminary scans were acquired.  The contrast solution was injected outside the 
scan room through a 1 mL syringe joined to the tubing with a 30 gauge needle.   
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Figure 4-1.  Photograph of subconjunctival catheter placement.   
Catheter remaining in the eye after subconjunctival insertion.  The open end is 
connected to a syringe located outside the scan room by 7 m of PE-10 tubing. 
 
 
4.2.2. MRI Setup 
Two 2 mL glass vials filled with PBS and the injection contrast solution were 
taped over the eye as reference standards.  The rabbit was placed on a cradle and the 
entire head inserted in a volume coil (Fig. 4-2).  T1-weighted images were acquired 
using a 3D gradient echo sequence.  The sequence parameters were: TR/TE = 40/5 
ms, FOV = 9 cm × 4.59 cm × 9 cm, matrix = 256 × 128 × 128, pulse angle 30° and 
NEX = 1.  The FOV was positioned to capture both eyes and the two standard 
solutions and the pixel resolution was 0.703 mm × 0.179 mm × 0.703 mm.  One scan 
was acquired before bolus injection with each scan lasting 11 minutes.  After 
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injection, scans were acquired in continuous succession for at least 3 hours for 60 and 
200 µl injections and 5 hours for 600 µl injections.  All rabbits were euthanized by 
pentobarbital overdose (200-250 mg/kg).  Rabbits used for in vivo experiments were 
euthanized immediately after completion of the experiment, while rabbits used for 
post mortem experiments were euthanized within one hour prior to the start of the 
scan.  A heating pad was used in post mortem experiments to maintain body 
temperature at 37 ˚C.  All experiments were repeated at least in triplicate. 
 
 
 
Figure 4-2.  Rabbit setup in magnet.   
(A) Rabbit after intubation, (B) rabbit head positioned inside volume coil, and (C) 
rabbit and cradle positioned inside the bore of the main magnet. 
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4.2.3. Image Analysis 
MR images were analyzed using a program written in MATLAB (Mathworks, 
Natick, MA) designed to read and display Bruker file images.  To convert signal 
intensities into concentration values of Gd-DTPA and Gd-albumin, a signal intensity 
vs. concentration calibration curve was constructed by scanning samples of varying 
concentrations of contrast agent in PBS using the same MR imaging parameters as 
the rabbit experiments.  The calibration curves were shown previously, in Figures 2-
11 and 2-13.  Since injections were performed using large solution volumes and most 
of the subconjunctival bleb consisted of fluid, PBS was assumed to adequately model 
the fluid-filled tissue.  The calibration curve was constructed by scanning the PBS 
samples using the same MR imaging parameters used for the rabbit experiments.   
To obtain concentration values of the contrast agent in the subconjunctival 
tissue after injection, the entire 3D image set was normalized to the signal intensity of 
the contrast agent standard at each time point.  The images were set to a threshold 
signal intensity level equivalent to a concentration of 0.03 mM for Gd-DTPA and 
0.005 mM for Gd-albumin (detection limit).  This allowed the subconjunctival bleb to 
be defined clearly as pixels containing only background noise and tissues with trace 
or no amounts of contrast agent were omitted.   
Analysis was performed on individual slices which were all taken from one of 
the three dimensions.  The in-plane resolution of the images used in analysis was 
0.703 × 0.179 mm.  For each slice that contained visible pixels in the subconjunctival 
tissue after thresholding, an ROI was manually drawn around the hyperintense bleb.  
The signal intensity of each pixel in the ROI was converted to a concentration of Gd-
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DTPA or Gd-albumin using the signal intensity vs. concentration calibration curve.  
After converting the signal intensity value to concentration for each pixel in the ROI, 
the mass of contrast agent in each pixel was computed by multiplying the pixel 
volume (0.089 mm3) by concentration.  By taking the sum of the mass of contrast 
agent in each slice, the total mass of contrast agent in the subconjunctival tissue was 
computed for each time point.  The number of pixels that were included in each ROI 
was also recorded and multiplied by the pixel volume to obtain the total volume of 
the subconjunctival tissue at each time point.  The average concentration of contrast 
agent in the subconjunctival tissue was calculated by dividing the total mass by the 
total volume.   
The mass clearance data was fit to an exponential function, M=Ae-kt, where M 
is the total mass of contrast agent in the subconjunctival space at time t, A is a 
constant, and k is the rate constant for clearance.  Regressions were performed using 
Microsoft Excel (Microsoft Corporation, Redmond, WA) on semi-log plots of M vs. 
time, and values of k were computed from each experiment.  The half-life was 
derived from the rate constant (t1/2 = 0.693/k).   
 
4.2.4. Cryotherapy Procedure 
 A previous study [52] utilized cryotherapy to selectively eliminate clearance 
of drug from choroidal circulation.  To examine the effect of cryotherapy on drug 
elimination after subconjunctival injection, cryotherapy was performed on the right 
eye of healthy rabbits at the injection site of the superotemporal quadrant.  A single 
freeze/thaw cycle was performed to preserve the conjunctival vasculature and sclera 
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and produce a chorioretinal scar.  A 2.5 mm retinal probe attached to a Keeler CTU 
CO2 cryo unit (Keeler Instruments, Broomall, PA) was used to perform cryotherapy 
at a temperature of -60 ˚C.  A total of eight adjacent cryotherapy applications in two 
horizontal rows were placed 4 mm from the limbus.  The rabbits were utilized for 
MRI scanning at least 4 weeks after mature chorioretinal scar formation.  Previous 
studies have indicated that this time frame is sufficient to ensure the permanent local 
damage of choroidal vasculature [52,171,172]. 
 The cryotherapy treated rabbits were scanned according to the same surgical 
and experimental procedures as outlined in previous sections, with the catheter placed 
directly over the cryo-treated site.   
 At least 3 cryotreated eyes were also enucleated and sectioned according to 
methods outlined in section 3.2.4. for histological analysis. 
 
4.3. Results 
Figures 4-3 and 4-4 show serial images acquired immediately after a 200 μl 
and 600 μl subconjunctival injection of Gd-DTPA, respectively.  The images show a 
comparison of the in vivo and post mortem scans.  The color bar indicates the 
concentration of Gd-DTPA determined after conversion from signal intensity.  
Immediately after injection, the Gd-DTPA solution appears as a localized depot in the 
subconjunctival space at a high concentration.  Over time, the concentration of Gd-
DTPA in the subconjunctival bleb decreases dramatically in vivo for both injection 
volumes.  About 3 hours post-injection of 200 μl and 4 hours post-injection of 600 μl, 
most of the Gd-DTPA molecules have disappeared from the depot in vivo.  However, 
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in the post mortem case for both injection volumes, the Gd-DTPA concentration 
decrease is not nearly as significant.   
   
 
 
Figure 4-3.  MRI scans of 200 μl Gd-DTPA.   
Images acquired during in vivo and post mortem experiments after 200 μl Gd-DTPA 
injection.  Times indicate minutes after injection.  The volume occupied by Gd-DTPA 
is also shown in red by 3-dimensional reconstruction. 
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Figure 4-4.  MRI scans of 600 μl Gd-DTPA.   
Images acquired during in vivo and post mortem experiments after 600 μl Gd-DTPA 
injection.   
 
 
 
The Gd-DTPA mass clearance data for 200 and 600 μl injection experiments 
is plotted in Figures 4-5A (in vivo) and 4-5B (post mortem).  The plots also show the 
regression lines for the exponential fit of the mass data.  Table 4-1 lists the average 
mass clearance rates (k) determined from individual regressions.  While the k value 
for the 600 μl injection data appears to be less than the k value for the 200 μl data in 
vivo, the results from a one-tailed Mann-Whitney U test reveals that this difference is 
not significant for p=0.05 (Table 4-2).  Similarly, the k value after a 60 μl injection 
(0.0372 min-1) is not significantly different from the k value after a 200 μl injection in 
vivo.  However, the difference in k values becomes significant when comparing the 
60 μl injection to the 600 μl injection data, as shown in Tables 4-1 and 4-2. 
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Contrast agent, injected 
volume 
k (in vivo) 
(min-1) 
Half-life 
(hrs) 
k (post mortem) 
(min-1) 
Half-life 
(hrs) 
Gd-DTPA, 60 μl 
 
0.0372 ± 
0.0032 
0.31 -------- ----- 
Gd-DTPA, 200 μl 
0.0273 ± 
0.0145 
0.42 
0.0029 ± 0.0007 
 
3.3 
Gd-DTPA, 200 μl, 
CRYO 
0.0336 ± 
0.0043 
0.35 -------- ----- 
Gd-DTPA, 600 μl 
0.0247 ± 
0.0071 
0.47 
0.0028 ± 0.0010 
 
4.1 
Gd-albumin, 200 μl 
0.0022 ± 
0.0010 
5.3 
0.0009 ± 0.0004 
 
12.8 
Table 4-1.  Summary of average rate constants ± SD acquired in vivo and post 
mortem.  
 
 
Figures 4-3 and 4-4 also present three-dimensional visual reconstructions of 
the apparent volume of Gd-DTPA, which were created by merging the slices that 
crossed through the subconjunctival bleb.  These reconstructions are shown adjacent 
to the MR images at each respective time point.  The apparent subconjunctival 
volume occupied by Gd-DTPA decreases dramatically in vivo while the post mortem 
scans show a slight increase in volume.  This effect is also shown in Figures 4-5C and 
4-5D which are plots of the apparent Gd-DTPA volume in the subconjunctival space.  
Figures 4-5E and 4-5F are plots of the average concentration of Gd-DTPA in the 
subconjunctival space.  They show a decrease in average concentration for all 
experiments. 
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Figure 4-5.  Plots comparing Gd-DTPA in vivo and post mortem.   
Gd-DTPA change in mass, apparent volume and average concentration after 200 μl 
and 600 μl subconjunctival injection in vivo (A, C, E) and post mortem (B, D, F).  
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Values are given as mean ± SD.  Lines indicate regression for mass clearance data.  r2 
values: =0.99, =0.99, =0.84, =0.97.   
 
 
 
Test Significantly different? 
In vivo vs. post mortem  
 Gd-DTPA, 200 μl yes 
 Gd-DTPA, 600 μl yes  
 Gd-albumin, 200 μl no 
Effect of volume, in vivo, Gd-DTPA  
60 μl vs. 200 μl  no 
200 μl vs. 600 μl  no 
60 μl vs. 600 μl  yes 
Gd-DTPA vs. Gd-albumin  
 in vivo, 200 μl yes  
 post mortem, 200 μl yes  
Cryo vs. control  
 Gd-DTPA, 200 μl, in vivo yes  
Table 4-2.  Results from the Mann-Whitney U test for U(0.05). 
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Figure 4-6.  MRI scans of 200 μl Gd-albumin.  
Images acquired during in vivo and post mortem experiments after 200 μl Gd-albumin 
injection.  The volume occupied by Gd-albumin is also shown in red by 3-
dimensional reconstruction. 
 
 
 
MR images from 200 μl injections of Gd-albumin are shown in Figure 4-6.  A 
comparison of the in vivo Gd-albumin images in Figure 4-6 to the in vivo Gd-DTPA 
images in Figure 4-3 for the 200 μl injection volume indicates that the concentration 
of Gd-albumin decreases more slowly with time compared to Gd-DTPA.  This 
observation is further substantiated by the quantitative representation of mass 
clearance given in Figures 4-7A (DTPA) and 4-7B (albumin).  The average in vivo 
half life of Gd-DTPA is 22 minutes and of Gd-albumin is 5.3 hours, as presented in 
Table 4-1.  Figures 4-7A and 4-7B also show that the post mortem decline of Gd-
albumin concentration is about 4 times slower than the post mortem decline of Gd-
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DTPA for the 200 μl injection experiments, as evidenced by the calculated half lives 
which are given in Table 4-1. 
The mass clearance data in Figure 4-7B shows a slightly faster decrease of 
Gd-albumin in vivo compared to Gd-albumin post mortem.  Table 4-1 gives the 
respective half lives as 5.3 hours in vivo and 12.8 hours post mortem.  However, a 
one-tailed Mann-Whitney U test (p=0.05) suggests that the difference between the in 
vivo and post mortem clearance rates is not significant for Gd-albumin (Table 4-2).     
The apparent volume of Gd-albumin shows a slight increase post mortem (Fig. 
4-8D).  A similar effect is seen in Figure 4-7C for the volume of Gd-DTPA post 
mortem.  The in vivo volume of Gd-DTPA shows a considerable decrease, whereas 
that of Gd-albumin is less prominent.  The faster decrease in volume of Gd-DTPA 
may reflect the higher clearance rate of Gd-DTPA than Gd-albumin from the 
subconjunctival space, since the volume decrease is due to the reduction in the 
number of pixels with signal intensities above the threshold. 
Figures 4-7E and 4-7F show a decrease in average concentration of Gd-
albumin in the subconjunctival space for all experiments.  This trend also correlates 
with the images shown in Figure 4-6, which show a slight decrease in the overall 
concentration of Gd-albumin. 
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Figure 4-7.  Plots comparing Gd-DTPA and Gd-albumin.   
Gd-DTPA (A, C, E) and Gd-albumin (B, D, F) change in mass, apparent volume and 
concentration after 200 μl subconjunctival injection in vivo and post mortem.  Values 
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are given as mean ± SD.  Lines indicate regression for mass clearance data.  r2 values: 
=0.99, =0.84, =0.94, =0.97.   
 
 
 
 Figure 4-8 shows a histological slide of the sectioned cryo-treated area after 
hemotoxylin and eosin staining.  The eye was enucleated 4 weeks after cryotherapy 
and sectioned into 10 micron slices.  The retina is shown to be effectively obliterated 
in the cryo area.  Table 4-1 shows that the k value from cryo-treated animals is 0.0336 
min-1.  From the Mann-Whitney U test, this is significantly different from the in vivo 
k value, 0.0273 min-1 (Table 4-2).  Therefore, cryotherapy significantly increases the 
mass clearance rate of Gd-DTPA after subconjunctival injection. 
 
 
 
Figure 4-8.  Sectioned cryo area after H&E staining.   
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4.4. Discussion 
Our study gives a quantitative comparison of the clearance of Gd-DTPA and 
Gd-albumin following subconjunctival injection in rabbits.  The clearance rates of 
Gd-DTPA and Gd-albumin were determined by measuring the changes in signal 
intensity by means of DCE-MRI and converting these values into mass.   
 
4.4.1. Gd-DTPA vs. Gd-albumin 
Results from in vivo experiments show that the mass decrease of Gd-DTPA is 
faster compared to that post mortem.  This indicates that there are dynamic clearance 
mechanisms that are present in vivo but not post mortem.  In vivo, drugs can be 
cleared from the subconjunctival depot by diffusion into surrounding tissues and also 
by entering lymphatic and blood vessels located in the conjunctiva [52,105].  Post 
mortem, drug elimination from the depot occurs mainly by diffusion since blood and 
lymphatic flow are presumed absent.  While the clearance rate of Gd-DTPA in vivo 
was substantially higher than that post mortem, the in vivo and post mortem clearance 
rates of Gd-albumin did not differ significantly.  This indicates that in vivo clearance 
mechanisms such as blood and lymph flow have a considerable effect on the 
elimination of Gd-DTPA but not on Gd-albumin.      
Gd-DTPA molecules are smaller (<1 nm) and lower in molecular weight than 
Gd-albumin (4 nm).  Drug absorption after subcutaneous injection has been shown to 
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decrease linearly with increasing molecular weight [173], and a similar dependence 
may exist after subconjunctival injection.  The disposition of nanoparticles following 
subconjunctival injection has been shown to display a size-dependence, with smaller 
particles reaching undetectable levels in the periocular tissue while larger particles 
were almost entirely retained [53].  Small drug molecules (<1 kDa) are thought to be 
preferentially absorbed by the blood capillaries while proteins larger than about 16 
kDa are taken up primarily by the lymphatic system [173,174].  The large molecular 
radius of Gd-albumin may hinder its entry into blood vessels so that clearance by 
blood flow is negligible.  However, lymphatic vessels permit the entry of large 
particles and Gd-albumin may be cleared by the lymphatics present in the 
conjunctiva.  Since albumin molecules are able to gain rapid access to lymphatic 
vessels but not to blood vessels, they are used in lymphatic flow studies which require 
administration by subcutaneous injection (Schornack, PA et al. Proc Intl Soc Mag 
Reson Med, ISMRM, 2001;58) [175,176].  Gd-DTPA, on the other hand, should be 
easily cleared by both blood and lymphatics because of its small size.  Our results 
show that the in vivo Gd-albumin clearance rate from the subconjunctival space was 
significantly slower than Gd-DTPA clearance rate by a factor of about 14, as seen 
from the values in Table 3-1.  These results may be indicative of the selective 
clearance of Gd-albumin through lymphatic vessels and the relatively low flow rate of 
lymph compared to that of blood [174].  Our results also show that the clearance rates 
of Gd-albumin in vivo and post mortem are not significantly different.  If Gd-albumin 
is cleared mostly by lymph and not by blood flow, this may suggest that lymphatic 
clearance after subconjunctival injection is not significant. 
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Maurice and Ota previously reported on the kinetics of subconjunctival 
injections in 1978 [170].  They reported that the half-life of 22Na was 9 minutes while 
that of albumin was 9 hours.  Our data shows that the half-life of Gd-DTPA after a 
200 μl injection in vivo is about 27 minutes, which based on its molecular size, fits 
reasonably with Maurice and Ota’s findings.  The half-life of Gd-albumin reported in 
our study (5.3 hours) also compares to the half life of 9 hours reported by Maurice 
and Ota.  The discrepancy may be explained by the difference in data acquisition, as 
Maurice and Ota measured radioactive-labeled albumin from sections of excised 
tissue from enucleated eyes.  For comparison to other tissues, Pain et al [177] 
reported a 3.6 hour half life for the clearance of albumin from subcutaneous injections 
in healthy human volunteers.  Their clearance data showed a single exponential decay 
over times up to three hours.   
 
4.4.2. Quantitation of MRI Results 
With the cessation of blood or lymph flow in the post mortem animal, a nearly 
zero clearance rate for both Gd-DTPA and Gd-albumin is expected.  In our study, the 
post mortem decrease in mass is most likely due to the diffusion of contrast agent 
molecules out of the subconjunctival space.  As molecules diffuse away from the 
subconjunctival depot, they will begin to fill the pixels that lie on the periphery of the 
injection site.  But many of these pixels will have very low concentrations of contrast 
agent and will remain below the threshold value (0.01 mM for Gd-DTPA and 0.005 
mM for Gd-albumin).  Although these pixels contain contrast agent molecules, they 
are removed during image analysis.  Therefore, the total mass of contrast agent 
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decreases over time because molecules are continuously moving from high to low 
concentration areas, increasing the number of molecules residing in pixels that fall 
below the threshold.  Since the diffusion of Gd-DTPA is faster than Gd-albumin, the 
post mortem “clearance” of Gd-DTPA is also faster than that of Gd-albumin.   
On the other hand, the apparent volume was reported to increase in post 
mortem experiments.  As molecules diffuse out of the depot, more molecules will 
enter the pixels surrounding the injection site.  This will increase the concentration of 
contrast agent and in some cases the increase may be sufficient for pixels to have 
values above the threshold.  These pixels are then counted as part of the 
subconjunctival depot during image analysis, and the volume will increase with time. 
The volume measured in our studies represents the apparent volume of 
contrast agent in the eye, not the volume of the subconjunctival bleb.  The changes in 
volume and mass of subconjunctival fluid may be different from that of the contrast 
agent.  While fluid clearance may affect solute clearance, the technique used in our 
study cannot distinguish between fluid and solute clearance, and other measurement 
methods are necessary to explore these mechanisms in detail.   
 
4.4.3. Effect of Injection Volume 
Our results also showed that there was no significant difference in clearance 
rate when comparing the 60 and 200 μl injections and the 200 and 600 μl injection 
volumes.  The clearance rate is significantly different, however, when comparing the 
60 and 600 μl injection volumes.  Previous studies using intramuscular injections 
reported a higher rate of absorption of hydrophilic drugs when the compounds were 
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administered in smaller injection volumes [178,179].  This is expected as a high 
interface area to injection volume ratio increases the drug absorption rate [180,181] 
and is in line with our results.  In our study, the Mann-Whitney U test results 
demonstrated that the clearance rate did not differ significantly until the volumes 
differed by an order of magnitude.  This indicates that the surface area to volume ratio 
will significantly alter the mass clearance rate when injection volumes differ by 10-
fold.    
The MRI results also show that larger injection volumes allow for longer 
retention times of contrast agent in the subconjunctival space.  A comparison of mass 
values after 200 and 600 μl injections shows that there are higher amounts of Gd-
DTPA in the subconjunctival space after the 600 μl injection at any given time point.  
This may be of clinical importance when longer retention times of drugs are required 
in the subconjunctival space to produce prolonged release of drug.   
 
4.4.4. Effect of Cryotherapy 
The results from the cryo-treated rabbits showed significantly faster clearance 
than normal rabbits.  This is a surprising result, since with the elimination of 
choroidal blood flow, the rate of mass clearance is expected to be reduced.  Gd-DTPA 
may have permeated to the vitreous at higher levels since cryotherapy may have 
significantly reduced the diffusional resistance provided by the retina (and probably 
also the RPE).  However, the accumulation of Gd-DTPA in the vitreous did not 
significantly increase, since Gd-DTPA concentrations were found to be below 
detection levels (< 0.03 mM) during the entire scanning period.  Therefore, this is a 
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puzzling result, since elimination has somehow increased after cryotherapy, despite 
the decrease in diffusional resistance.  This result prompts further investigation on the 
physiological changes that occur after cryotherapy and whether there are any 
alterations in blood flow or permeability to ocular tissues before cryotherapy becomes 
an established model for selective elimination of choroidal clearance. 
 
4.4.5. Limitations in DCE-MRI Technique 
There are several limitations of the DCE-MRI technique used in our study.  
The concentration range of contrast agent detected by our DCE-MRI method is only 
about 2 log units.  The effect of dose on clearance rate could not be studied due to the 
narrow concentration detection range.  Concentration changes occurring beyond this 
range are undetectable with our technique and more sensitive methods such as 
measurement of T1 may be required.  The differences in relaxation times of PBS and 
subconjunctival tissue may contribute to error in the conversion of signal intensity to 
concentration, because our calibration was based on PBS and not on subconjunctival 
tissue.  However, since the subconjunctival bleb is comprised mostly of fluid and not 
tissue, we assumed that PBS would adequately model the subconjunctival bleb.  Also, 
our choice of Gd-DTPA as a low molecular weight model drug may not be fully 
adequate since Gd-DTPA is a hydrophilic molecule and may exhibit pharmacokinetic 
behavior that is different from lipophilic drugs.  In following animal care and use 
guidelines, inhalational isoflurane was required to maintain general anesthesia.  
Clearance rates may be different in an anesthetized vs. a non-anesthetized animal, as 
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the effect of inhalational isoflurane on blood and lymphatic flow in the eye is 
unknown. 
In this study, a volume coil was utilized and therefore high resolutions 
produced in prior studies (Chapter 3) using a surface coil could not be achieved.  
However, a volume coil allows a bigger FOV to capture standard phantoms and the 
contralateral eye.  For this study, since high spatial resolution was not as critical as 
temporal resolution, a volume coil could be used to acquire the necessary data for this 
analysis.   
 
4.5. Conclusion 
DCE-MRI is a useful technique that allows non-invasive in vivo data 
measurement in real-time.  Our study demonstrates that sufficient spatial and 
temporal resolution can be achieved with DCE-MRI to capture the kinetic changes of 
subconjunctival drug clearance.  DCE-MRI also enables the quantitation of data 
through the conversion of signal intensity to concentration.  Results from 
subconjunctival injections of Gd-DTPA and Gd-albumin indicate that active 
clearance mechanisms (such as lymphatic and blood flow) can affect drug elimination 
rates.  Lymphatic clearance does not seem to be as significant as clearance by blood, 
as evidenced by data from Gd-albumin injections.  Injection volume significantly 
decreases the clearance rate when increased 10-fold, and higher injection volumes 
allow for longer retention times of drug. 
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Chapter 5:  A Model of Subconjunctival Drug Delivery  
5.1. Introduction 
Although many ocular pharmacodynamic studies have been reported in the 
literature, the pharmacokinetics in the eye after drug delivery needs more elucidation.  
The number of ocular pharmacodynamic studies is far greater than pharmacokinetic 
studies, and this is particularly true for periocular (i.e. transscleral) drug delivery 
studies [182].  As a result of the lack of periocular pharmacokinetic data, modeling 
efforts have been hindered as many pharmacokinetic parameters remain unknown.   
In an effort to better explore the drug barriers and clearance mechanisms 
present in the eye, a finite element model of transscleral drug delivery by 
subconjunctival injection was created using COMSOL and the results were compared 
to MRI data.  Finite element modeling enables distributed pharmacokinetic modeling, 
which incorporates both temporal and spatial information of drug distribution [183].  
On the contrary, compartmental models assume that the drug is distributed 
homogeneously in each tissue or organ.  In modeling local ocular drug delivery, 
compartmental models may not accurately represent the distribution of drugs in eye 
tissues since steep drug concentration gradients are often established due to the 
complexity of drug transport barriers present in the eye.  Therefore, distributed 
models may be of greater interest and may provide more accurate information 
regarding local ocular drug delivery. 
As previously discussed, drug measurements in eye tissues are traditionally 
reported as a total mass or average concentration value.  Because tissues are 
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processed and analyzed in their entirety, information regarding the spatial distribution 
of drugs is lost.  Therefore, many current pharmacokinetic models of drug delivery in 
the eye are compartmental models [133,184], reflecting the manner in which drug 
measurements have been acquired in ocular delivery studies.   
In this research, in vivo temporal and spatial drug distribution information was 
acquired by utilizing MRI.  The results from MRI experiments were used to compare 
the results from a finite element model defined using literature values.  To date, the 
most investigative modeling on subconjunctival delivery has been performed by Lee 
and Robinson [185-187], in which the subconjunctival space and the vitreous 
chamber are modeled as compartments (Fig. 5-1).  Figure 5-2 shows a proposed 
(unsolved) subconjunctival compartmental model accounting for the intermediary 
tissues [133].  A more recent study performed by Mac Gabhann et al [188] describes 
a one-dimensional distributed model of protein delivery to the retina after 
subconjunctival injection (Fig. 5-3).  Currently, this is the only model in the literature 
that explicitly accounts for the distinct transport properties of each of the ocular wall 
tissues (sclera, choroid and retina).  Finite element modeling has previously been used 
to model drug distribution within the vitreous compartment [57,58,189,190] after 
intravitreal delivery.  However, a finite element model has not yet been reported for 
transscleral (including subconjunctival) drug delivery.   
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Figure 5-1.  A simple compartmental pharmacokinetic model of subconjunctival 
injection.   
From Lee, 2004 [186].   
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Figure 5-2.  A proposed compartmental pharmacokinetic model of 
subconjunctival injection.   
From Ranta, 2006 [133].  
 
 
 
 
Figure 5-3.  A distributed pharmacokinetic model of subconjunctival injection.   
From Mac Gabhann, 2007 [188]. 
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5.2. Methods 
5.2.1. Model Geometry 
 A two-dimensional axisymmetric geometry was created in COMSOL 
Multiphysics™ 3.3a (Burlington, MA) using the Chemical Engineering Module to 
resemble the anatomy of the tissues involved during subconjunctival delivery.  The 
model was designed to simulate a 200 µl bolus subconjunctival injection of Gd-
DTPA.  Figure 5-4 shows the model geometry which includes 7 subdomains: adipose 
tissue, conjunctiva, the injected drug bolus, sclera, choroid, retina, and vitreous.  The 
RPE was not drawn as a separate subdomain but was modeled as a thin resistance 
layer with a thickness of 10 microns [191].    
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Figure 5-4.  Model geometry in r-z plane.   
Numbers indicate dimensions in meters.   
 
 
 The bolus was drawn as an ellipsoid with a radius of 0.007 m and height of 
0.002 m to yield a volume of 205.25 μl, simulating a 200 μl injection.  The radius and 
height of the injection solution domain were specified to match the radius and height 
of the bolus imaged from MRI experiments.   The conjunctiva was drawn as an 
elliptical shell enveloping the outer side of the bolus and the remaining compartments 
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were drawn as cylindrical discs.  The thicknesses of the choroid and retina were 
determined by measuring the tissue thicknesses of the albino rabbit choroid and retina 
from histology slides (Table 5-1).  Adipose tissue was included as a subdomain 
outside the conjunctiva, since it surrounds the orbit, acting as a cushion for the 
eyeball [192].  The model was reduced to a quarter of the original geometry to 
minimize solver time and memory requirements. 
 
 
Tissue Thickness (m) Reference 
Sclera 0.0003 Fatt, 1970 [193] 
Choroid 0.00006 Measured in histology slides 
Retina 0.00009 Measured in histology slides 
Table 5-1.  Tissue thickness values used in model. 
 
 
 The geometry was meshed using triangular elements resulting in 33120 
elements and 69223 degrees of freedom (Figure 5-5).  The model was solved for 
times from 0 to 3 hours at 11 minute increments to correspond to the MR image 
acquisition time.  Model solver times were approximately 90 seconds. 
 
 
 108 
 
 
Figure 5-5.  Meshed geometry in r-z plane.   
 
 
5.2.2. Model Parameters 
5.2.2.1. Governing equation 
A transient diffusion analysis was specified for the model geometry, and 
transport by convection was ignored.  Therefore, the governing mass transport 
equation is described by: 
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where C is the whole tissue concentration of Gd-DTPA, D is the whole tissue 
diffusion coefficient, and R is the reaction rate.  For tissues with significant cellular 
mass, extracellular parameters were taken into account: 
ee
ee
DD
CC
φ
φ
=
=
      (2) 
where φ is the extracellular void volume fraction.  Void fractions for various tissues 
are given in Table 5-2.  The void volume fraction has not been reported for the 
conjunctiva, and it was estimated that the void fraction would be the same as that of 
the choroid since the conjunctiva is cellular and includes vascularity.   
 
 
Tissue Void fraction (φe) Reference 
Adipose 0.1 Linde and Chisolm, 1975 [194] 
Conjunctiva 0.4 estimate 
Sclera 0.8 Mac Gabhann, 2007 [188] 
Choroid 0.4 Mac Gabhann, 2007 [188] 
Retina 0.3 Mac Gabhann, 2007 [188] 
Table 5-2.  Model values of extracellular void volume fraction. 
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5.2.2.2. Diffusion coefficients 
 Diffusion coefficients were assigned to each subdomain.  The injection bolus 
was assigned the diffusion coefficient of Gd-DTPA in water (Table 5-3), since the 
injection solution consisted of Gd-DTPA in PBS.  The diffusion coefficient of Gd-
DTPA in the vitreous was also assumed to be equal to that in water.  The calculation 
of the diffusion coefficient of Gd-DTPA in various subdomains is described in the 
Appendix.  The diffusion coefficient of the RPE was determined by using the 
permeability value of sodium fluorescein (NaF) across the Bruch’s membrane-
choroid and RPE [195].  NaF has similar physicochemical properties as Gd-DTPA in 
molecular weight (376 Da) and hydrophilicity.   
 
 
Subdomain Diffusion coefficient (m2/s) 
Injection solution 5.3e-10 
Conjunctiva 2.2e-10 
Adipose tissue 2.0e-10 
Sclera 2.6e-10 
Choroid 2.2e-10 
RPE 4.9e-13 
Retina 2.1e-10 
Vitreous 5.3e-10 
Table 5-3.  Model parameters: diffusion coefficients. 
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5.2.2.3. Clearance rates 
 MRI data from Chapter 3 suggested that lymphatic flow may not be a 
significant contributor to drug clearance in the eye.  In addition, while adipose tissue 
is vascularized [196], the presence of lymphatics is still debated [197].  Therefore, 
blood flow was regarded as the sole contributor to in vivo clearance in this modeling 
study.  Clearance by blood flow was simulated by including a reaction (clearance) 
rate term (R) in the conjunctiva, choroid, and adipose tissue.  The clearance rate was 
assumed to be first-order: 
CCLR ×=       (3) 
 
(where CL is a constant) since in most instances, the first-order approach is regarded 
as a reasonable approximation for many drug absorption processes in the body [198].  
 The clearance constant CL was defined using the equation for capillary 
clearance developed by Kety, Renkin and Crone [199-201]: 
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e
V
QCL 1      (4) 
 
where P is the capillary permeability, S is the capillary surface area, Q is the tissue 
blood flow rate, and V is the volume of distribution.  Values for PS and Q were 
gleaned from the literature and are summarized in Tables 5-4 and 5-5.   
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 The capillary surface area of the choriocapillaris was estimated by multiplying 
the surface area of the choroid (8 cm2; [134]) by 3/2, similar to the method used by 
Bill et al [202].   The conjunctival capillaries are nonfenestrated, similar to those 
found in skeletal muscle [203].  Since values of PS and Q for the conjunctiva have 
not been reported, values for skeletal muscle were used instead.  Values for 51Cr-
EDTA were used since 51Cr-EDTA is commonly used in perfusion studies and its 
physicochemical properties are similar to that of Gd-DTPA (51Cr-EDTA is also lipid-
insoluble and has a molecular weight of 357 Da).   
 
 
Tissue Species P (cm/s) S (cm2) PS (g/s) 
Choroid 
(choriocapillaris) 
Rabbit 7e-4*  [204] 12   0.0084  
Skeletal muscle Cat --------- -------- 0.0002* [205] 
Table 5-4.  Literature values and calculated values of PS. 
*Reported value for 51Cr-EDTA.   
 
 
 
Tissue Species Q (g/s) 
Choroid Rabbit 0.0135 [158]  
Skeletal muscle Human 0.0001* [206] 
Table 5-5.  Literature values of Q. 
*value scaled for rabbit conjunctiva. 
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 The volume of choroidal tissue was calculated by multiplying the tissue 
thickness (0.006 cm) by the surface area (8 cm2) and regarding tissue density as that 
of water (1 g/cm3).  Likewise, the volume of conjunctival tissue was calculated using 
an estimated tissue thickness (0.03 cm) multiplied by the surface area (8 cm2; [207]).  
This yielded values of 0.048 g and 0.24 g for volumes of the choroid and conjunctiva, 
respectively.   
 Table 5-6 shows the CL values calculated from equation (4) for the 
conjunctiva and choroid.   
 
 
Subdomain CL (s-1) 
Adipose tissue -0.0003* [208] 
Conjunctiva -0.00041 
Choroid  -0.13 
Table 5-6.  Calculated clearance rate constants for in vivo models. 
*Reported value for 51Cr-EDTA in rabbit. 
 
 
 
 From equation (4), if PS<<Q,  
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V
PSCL ≈      (5) 
 
the clearance rate becomes diffusion limited.  Similarly, if PS>> Q, 
V
QCL ≈       (6) 
 
and the clearance rate becomes blood flow limited.  The clearance constant for 
adipose tissue was assumed to be diffusion-limited since the vessels are 
nonfenestrated and a perfusion rate could not be found from the literature.  In 
addition, the diffusion-limited CL value is not expected to differ significantly from 
the perfusion-limited value (as is the case for the conjunctiva, indicated from the 
values listed in Tables 5-4 and 5-5). 
For models simulating post mortem delivery (no blood flow), CL was set 
equal to 0. 
 
5.2.2.3. Boundary and Initial conditions 
 All outside boundaries were set to insulation (zero flux), and the interior 
boundaries were assigned as continuity except at the RPE boundary, which was 
specified as a thin boundary layer (Figure 5-6).  The initial conditions were specified 
as1 mM for the injection bolus and 0 mM for all remaining subdomains.   
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Figure 5-6.  Boundary conditions.   
 
 
5.3. Results 
5.3.1. Post mortem  
 Figure 5-7 shows the results from the post mortem model simulation at time=0 
minutes post-injection.  A thresholding of 0.03 mM was applied to the images to 
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match the detection limit of the MR images.  The injection depot subdomain is at the 
initial concentration of 1 mM and the remaining subdomains are at 0 mM.  Figure 5-8 
shows the change in concentration with time and space.  At 11 minutes post-injection, 
a significant amount of Gd-DTPA has diffused into the surrounding subdomains.  By 
55 minutes, a low concentration of Gd-DTPA can be detected in the conjunctiva and 
portions of the adipose tissue as the contrast agent molecules are diffusing out of the 
bleb.  By 3 hours, low levels of Gd-DTPA can be seen in most of the surrounding 
tissues including the vitreous.   
  
 
Figure 5-7.  Model result at t=0 min post-injection (initial condition).   
Color scale shows the concentration range in mM units.   
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Figure 5-8.  Concentration changes of Gd-DTPA with time and space in the post 
mortem model.   
Color scale shows the concentration range in mM units.  Times represent minutes 
after injection. 
 
 
 Figure 5-9 shows the concentration profiles from the center axis of symmetry, 
r=0.  High concentrations remain within the injection depot but steep gradients are 
observed on either side of the subconjunctival subdomain.  The RPE provides high 
diffusional resistance between the choroid and retina (Fig. 5-10), resulting in very low 
concentrations in the retina and vitreous.   
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Figure 5-9.  Concentration profiles from the post mortem model of Gd-DTPA 
through the center axis of symmetry, r=0.   
Lines represent concentration profiles at 11 minute increments from 11-187 minutes 
post-injection. 
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Figure 5-10.  Increased magnification of concentration profiles shown in Figure 
5-9.   
 
 
 Figure 5-11 shows a plot of the mass decrease of Gd-DTPA comparing the 
model results to the MRI data.  To obtain mass values of Gd-DTPA from the model, 
mass integration was performed on all subdomains at each time point for those 
elements that had concentration values above the specified threshold of 0.03 mM.  
The resulting k value for the post mortem model is 0.0008 min-1.  This is significantly 
different from the MRI experimental result (k = 0.0041 min-1).   
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Figure 5-11.  A comparison of the mass clearance of Gd-DTPA from the post 
mortem model and the MRI data.   
Equations used in exponential regression also shown as y=Ae-kx, where k is the mass 
clearance rate in min-1.   
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Figure 5-12.  A comparison of the distribution volume of Gd-DTPA from the 
post mortem model and the MRI data.   
 
 
 Figure 5-12 shows the change in apparent distribution volume from the model 
and data results.  The volume was determined in a similar manner to the mass 
calculation, by integrating over all subdomains at each time point only for those 
elements that had concentration values above the threshold.  The volume increases 
significantly from the post mortem model results compared to the experimental MRI 
data. 
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5.3.2. In vivo  
 Figure 5-13 shows the change in concentration with time and space from the 
in vivo model simulation.  Gd-DTPA concentration in the bolus rapidly decreases 
with time, similar to the trend seen from the in vivo MRI experiments.  Low 
concentrations of Gd-DTPA can be seen penetrating into the adipose tissue, 
increasing the apparent volume occupied by Gd-DTPA.  However, the rapid 
clearance of the choroid effectively prevents the visible accumulation of Gd-DTPA in 
the vitreous.    
 
 
 
Figure 5-13.  Concentration changes of Gd-DTPA with time and space in the in 
vivo model.   
 
 123 
 
   
 
 
 
Figure 5-14.  Concentration profile results from the in vivo model of Gd-DTPA 
through the center axis of symmetry, r=0.   
 
 
 The effect of choroidal clearance on preventing significant Gd-DTPA 
penetration to the retina and vitreous is more clearly seen from the concentration 
profiles in Figures 5-14 and 5-15.  A steep concentration gradient is established in the 
sclera due to the rapid choroidal clearance.  The RPE provides a high diffusional 
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barrier that dramatically reduces the concentration of Gd-DTPA in the retina and 
vitreous (Figure 5-15). 
 
 
. 
 
Figure 5-15.  Increased magnification of concentration profiles shown in Figure 
5-14.   
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Figure 5-16.  A comparison of the mass clearance of Gd-DTPA from the in vivo 
model and the MRI data.   
 
  
 Figure 5-16 shows the mass clearance plot comparing the model results to the 
MRI data.  The model results follow the decreasing trend of MRI data in mass 
clearance.  The k values from the model and MRI data are comparable (k=0.0144 and 
0.0214 min-1, respectively).   
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Figure 5-17.  A comparison of the distribution volume of Gd-DTPA from the in 
vivo model and the MRI data.   
 
 
 Figure 5-17 compares the changes in apparent volume of the model and MRI 
data.  The model predicts an initial increase in volume with a peak time at around 22 
minutes before exhibiting decrease in volume.  This trend is also displayed by the 
MRI data.  The rate of volume decrease is similar for both the model and the MRI 
data but the model shows a much higher volume of distribution of Gd-DTPA. 
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5.3.3. Effect of thresholding 
 Analysis performed without thresholding in the in vivo model produces a k 
value (0.0132 min-1) that is slightly lower than the k value determined after 
thresholding at 0.03 mM (0.0144 min-1).  The mass clearance rate is decreased when 
thresholding is not applied since elements with concentrations less than 0.03 mM are 
included in the concentration integration, increasing the total mass.  After 
thresholding, the concentration values in the retina and vitreous are shown to be near 
zero (Figure 5-15), but more significant concentrations may actually be present in 
these tissues.   
 Figure 5-18 shows the individual tissue average concentrations of Gd-DTPA 
without thresholding in vivo.  The plot indicates that the concentrations in the 
conjunctiva and sclera are one log less than the adjacent injection bolus.  Average 
concentration levels in the choroid are about 2-3 log units below the injection 
concentration, and concentrations in the retina and vitreous are about 4 orders of 
magnitude below the injection concentration. 
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Figure 5-18.  Individual average tissue concentrations of Gd-DTPA from the in 
vivo model.   
 
  
5.3.4. Sensitivity analysis 
 A sensitivity analysis was performed by varying the diffusion coefficients and 
clearance constants in the in vivo model.  All parameters were doubled in value 
(except run 5, where the permeability of the RPE is increased by an order of 
magnitude) and solved as a separate run.  Table 5-7 summarizes the values varied in 
each run. 
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Run # 1 2 3 4 5 6 7 
Subdomain 
Diffusion 
Coefficient 
(m2/s) 
      
sclera 2.60E-10 5.20E-10 2.60E-10 2.60E-10 2.60E-10 2.60E-10 2.60E-10
conjunctiva 2.20E-10 2.20E-10 2.20E-10 2.20E-10 2.20E-10 2.20E-10 2.20E-10
vitreous 5.30E-10 5.30E-10 5.30E-10 5.30E-10 5.30E-10 5.30E-10 5.30E-10
adipose 2.00E-10 2.00E-10 2.00E-10 2.00E-10 2.00E-10 2.00E-10 2.00E-10
choroid 2.20E-10 2.20E-10 4.40E-10 2.20E-10 2.20E-10 2.20E-10 2.20E-10
retina 2.10E-10 2.10E-10 2.10E-10 4.20E-10 2.10E-10 2.10E-10 2.10E-10
injection 5.30E-10 5.30E-10 5.30E-10 5.30E-10 5.30E-10 5.30E-10 5.30E-10
RPE 4.90E-13 4.90E-13 4.90E-13 4.90E-13 4.90E-12 4.90E-13 4.90E-13
Subdomain CL (s-1)       
conjunctiva -0.00041 -0.00041 -0.00041 -0.00041 -0.00041 -0.00041 -0.00082
adipose -0.0003 -0.0003 -0.0003 -0.0003 -0.0003 -0.0003 -0.0003 
choroid -0.13 -0.13 -0.13 -0.13 -0.13 -0.26 -0.13 
Table 5-7.  Model parameters varied for sensitivity analysis. 
Varied parameters are highlighted in blue. 
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Figure 5-19.  Effect of varying the diffusion coefficient of various tissues on mass 
clearance rate.     
Regression lines and equations are given for runs 1, 2 and 5. 
 
 
 
 Mass clearance plots from runs 1-5 are shown in Figure 5-19.  Changing the 
permeability of the choroid (run 3) and retina (run 4) did not significantly alter the 
mass clearance rate.  Doubling the permeability of the sclera (run 2) resulted in the 
most significant change in k value (0.0148 min-1).  Increasing the permeability of the 
RPE (run 5) by an order of magnitude decreased the mass clearance rate (0.0113 min-
1), since this allows higher amounts of Gd-DTPA to accumulate in inner tissues such 
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as the retina and vitreous.  This effect can be seen from the concentration profiles in 
Figure 5-20.   
 
 
 
Figure 5-20.  Effect of doubling RPE permeability on tissue concentration.   
Solid lines correspond to run 1, dashed lines correspond to run 5.  Represented times: 
11, 55, 121, and 187 minutes post-injection. 
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 Doubling either the choroidal or conjunctival clearance constant produced 
negligible changes in mass clearance rate.  The k values were 0.137 and 0.139 min-1 
for runs 6 and 7, respectively. 
 
5.3.4. Conjunctival vs. choroidal clearance 
The theoretical model can also be used to understand the effect of various 
transport barriers in the eye.  The separate contribution of conjunctival and choroidal 
clearance in drug elimination was investigated by running the in vivo model with an 
absence of clearance in either the conjunctiva or the choroid.  The resulting mass 
clearance values (k) are shown below in Table 5-8.   
 
  
 k (min-1) 
In vivo model 0.0132 
No conjunctival clearance model 0.0112 
No choroidal clearance model 0.0020 
Post mortem model 0.0008 
Table 5-8.  Summary of mass clearance values (k) from model simulations. 
 
 
 Eliminating conjunctival clearance produces a slightly lower mass clearance 
value than the in vivo model result.  Eliminating choroidal clearance drastically 
reduces the k value, resulting in a low clearance rate which is comparable to the post 
 
 133 
 
mortem k value.  These model simulations show that the choroidal clearance term 
needs to be included in order to produce results that resemble the in vivo results.  
Conjunctival clearance (without choroidal clearance) is not sufficient to clear the high 
amounts of drug from the subconjunctival depot as seen from in vivo studies.  
Therefore, in vivo, a significant fraction of the delivered amount of drug must be 
cleared by the choroid.  The model indicates that the choroid plays a more significant 
role in the clearance of drugs after subconjunctival injection than the conjunctiva, 
which is in contrast to several current papers which suggest that the conjunctiva may 
play a more significant role [52,209].   
 
5.3.5. Unidirectional Implant 
A recent paper explored the use of a unidirectional implant that permitted NaF 
release toward the choroid exclusively [56].  Drug exposure to the conjunctival 
clearance mechanisms was minimized by the use of this unidirectional implant.  
Higher amounts of NaF were detected in the retina by use of in vivo fluorophotometry 
after delivery by the implant than compared to a bolus injection.  To investigate the 
effect of unidirectionality on drug delivery to target tissues (choroid and retina), an 
impermeable boundary was established in the in vivo model by assigning a very low 
diffusion coefficient (10-20 m2/s) over a 10 micron thickness at the interface between 
the injection depot and the conjunctiva. 
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Figure 5-21.  Concentration profiles from the unidirectional model simulation.   
 
 
 
Figure 5-21 shows that by the implementation of the low diffusion coefficient 
at the boundary between the injection depot and the conjunctiva, Gd-DTPA is forced 
to penetrate toward the choroid and no concentrations of Gd-DTPA are detected in 
the conjunctiva.  Despite the reduced exposure to the conjunctiva, steep gradients are 
established in the sclera and choroid and negligible concentrations of Gd-DTPA are 
found in the retina and vitreous.   
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Figure 5-22.  Comparison of average concentration levels in target tissues after 
delivery by unidirectional implant and bolus injection.   
Triangles: unidirectional implant; squares: bolus injection 
 
 
  
 Figure 5-22 shows a comparison of the Gd-DTPA concentrations in target 
tissues (choroid and retina) after delivery by the unidirectional implant and by bolus 
injection.  The plot shows that the concentration levels are almost identical in the 
target tissues in these delivery methods.  The k value for the unidirectional implant is 
0.0112 min-1, which is the same as the k value determined from the model without 
conjunctival clearance (Table 5-8).  Therefore, the use of a unidirectional implant will 
produce the same effect as selectively eliminating conjunctival clearance.   
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5.4. Discussion 
5.4.1. Model vs. MRI results  
The post mortem model predicted a decrease in total mass of Gd-DTPA in 
ocular tissues, but the k value is about 5 times less than that from the MRI results.  
The k value predicted by the in vivo model, however, is only about 1.5 times less than 
that from the MRI results.  The in vivo k values from the model and MRI can be 
considered comparable, but the discrepancy in the post mortem k values is more 
significant.   
One explanation for the large difference post mortem may be the effect of 
rigor mortis in post mortem scans.  Immediately after death, rigor mortis decreases T2 
relaxation in tissues as they stiffen.  As shown in Figure 5-23, as T2 decreases, signal 
intensity also decreases.  This may account for the more rapid “clearance” of Gd-
DTPA in post mortem MRI scans, as Gd-DTPA present in surrounding tissues may 
not produce sufficient signal intensity to be detected on MR images.     
 
Figure 5-23.  The effect of T2 on signal intensity at a specified TE.  
From reference [136]. 
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In this research, signal intensities were used to determine the concentration 
and mass of Gd-DTPA.  Therefore, the accuracy in the conversion of signal intensity 
to concentration will always have a major effect on the results.  As discussed in 
previous chapters, the use of PBS phantoms may not correctly reflect the signal 
intensity changes with concentration in tissues.  In the results from the post mortem 
model, a significant portion of Gd-DTPA concentration is detected in tissues outside 
the injection bolus.  Some of the discrepancy between the model and data may be due 
to differences in relaxation rates in ocular tissues, resulting in an incorrect conversion 
of signal intensity from the use of a calibration curve based on PBS in tissue regions.     
Another reason for the faster mass decrease in the MRI post mortem scans 
may be due to the effect of volume averaging.  The MR images show average 
concentrations in each voxel and the finite element model shows average 
concentrations determined in each element.  The voxel size in MR images is 0.703 
mm × 0.179 mm × 0.703 mm and is relatively large compared to tissue thickness 
(conjunctiva is about 0.3 mm).  Some voxels may lie in areas where they encompass 
2 or more regions that have significantly different concentration values (especially at 
tissue boundaries).  As the voxel assumes an average concentration value, if the 
average is sufficiently low, it may fall below the concentration threshold.  This will 
result in fewer voxels that remain after thresholding, and will decrease the total 
amount of Gd-DTPA detected.  As less voxels are found to be above the 
concentration threshold, a faster decrease in total mass will result.  The decrease in 
the number of voxels will also decrease the apparent volume.     
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On the other hand, the finite element model is highly discretized and is 
composed of elements that are much smaller compared to the MR image voxels.  
Therefore, the model is better able to capture regions that have steep concentration 
gradients or regions that have low concentrations (but higher than 0.03 mM) of Gd-
DTPA.  The large apparent volume predicted by the model reflects the large area into 
which Gd-DTPA has diffused in the adipose tissue and vitreous, but is not detected 
by MRI.   
The effect of volume averaging also applies to the in vivo MRI scans, and 
therefore the k values from these experiments may be an overestimate.  Then there 
may actually be a smaller difference in k values from the model and MRI results, 
indicating that the model produces very reasonable results which are in line with the 
experimental data.   
 
5.4.2. Concentration levels in individual tissues  
When thresholding is applied to MR images, regions of low concentrations of 
Gd-DTPA cannot be observed.  The in vivo model results without thresholding gives 
an estimate of the low concentration levels of Gd-DTPA that are found in various 
tissues including the retina and vitreous, where concentrations are typically very low.  
As shown in Figure 5-18, drug levels in the choroid are about 2-3 log units below the 
administered concentration and about 4-5 log units below the injection concentration 
in the retina and vitreous.  The model can be useful in predicting the low 
concentration levels of drug in individual tissues, which may be more difficult with 
current MRI methods due to limitations in spatial and temporal resolution.   
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5.4.3. Sensitivity Analysis 
Sensitivity analysis was performed by doubling the diffusion coefficients and 
clearance rate constants.  Doubling the diffusion coefficient did not have a major 
effect on mass clearance rate except in the sclera, where the higher diffusion 
coefficient resulted in greater clearance, most likely through the choroid.  Absorption 
enhancers have been proposed to increase transscleral drug delivery of drugs by 
increasing the permeability of the sclera [21,210,211], but their therapeutic efficacy 
for posterior segment disorders has not been demonstrated in vivo.  Increasing the 
permeability of the RPE by one log unit permitted greater amounts of Gd-DTPA to 
accumulate in the retina and vitreous.  Therefore, increasing the permeability of the 
RPE may be a more effective method for increasing drug delivery to the retina.   
Doubling the clearance rate either in the conjunctiva or the choroid produced 
negligible changes in mass clearance rate.  An explanation for the mostly 
insignificant changes in clearance rate resulting from the sensitivity analysis may be 
found by comparing the significance of drug elimination in each tissue due to tissue 
permeability (Rp) and tissue clearance rate (Rc).   
The rate of drug elimination from a tissue is determined by the rate of 
permeation of the drug through the tissue (Rp): 
δ
SD×  (where D: tissue diffusion 
coefficient, S: surface area and δ: tissue thickness) and the rate of clearance by blood 
flow (Rc): VCL× (where CL: clearance rate determined from equation 4 and V: tissue 
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volume).  Table 5-9 shows the calculated rates of Rp and Rc in the conjunctiva and 
choroid. 
 
 
Tissue 
δ
SDRP
×
=  VCLRC ×=  
Conjunctiva 
0.021 g/min 
(D: 2.2e-10 m2/s 
S: 4.78e-4 m2 
δ: 0.0003 m) 
0.0029 g/min 
(CL: 0.00041 s-1 
V: 0.24 g) 
Choroid 
0.10 g/min 
(D: 2.2e-10 m2/s 
S: 4.52e-4 m2 
δ: 0.00006 m) 
0.21 g/min 
(CL: 0.13 s-1 
V: 0.048 g) 
 Table 5-9.  Comparison of RP and RC in the conjunctiva and choroid. 
 
   
The values for Rp and Rc in the choroid are significantly higher than that in the 
conjunctiva.  This indicates that drug clearance in the choroid is much more 
significant than clearance in the conjunctiva.  The table also shows that the Rp and Rc 
values are similar in the choroid, but they differ by an order of magnitude in the 
conjunctiva.  This shows that more drug molecules are removed from the conjunctiva 
by diffusion of the drug out of the tissue rather than by clearance through conjunctival 
blood vessels.  Therefore, the lower value, Rc, is rate-limiting in the conjunctiva, and 
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in order to produce a significant increase in drug clearance, Rc must be increased as 
increases in Rp will not have an effect.  In this sensitivity analysis, the effect of 
doubling CL was investigated, but greater changes in CL may be required to see 
significant increases in mass clearance rate. 
In the choroid, diffusion of the drug out of the tissue and clearance of the drug 
through the choroidal circulation are both equally high in magnitude.  Nevertheless, 
Rp is rate-limiting, and since in this sensitivity analysis Rc was altered, this did not 
produce a significant change in mass clearance rate.   
This analysis provides useful information regarding the drug clearance 
mechanisms in the choroid and conjunctiva.  The high permeability of the conjunctiva 
and choroid is advantageous in transscleral drug delivery since diffusion is the most 
significant method of intraocular drug transport.  The low clearance rate in the 
conjunctiva is also beneficial, but the rapid clearance in the choroid will significantly 
decrease the bioavailability of drug in the eye.  If drug clearance through the 
choroidal circulation can be decreased, a much greater yield in the retina will result.  
One method to decrease choroidal clearance is to increase the drug size by 
encapsulating the drug inside nano- or microparticles.  Substantial increases in drug 
size will hinder the diffusion of drugs through ocular tissues, but will also decrease 
the diffusion of drugs into the choroidal vessels as well.  Several recent studies have 
shown the successful delivery of particles to the retina after subconjunctival injection 
[12,13,212].  These particles have been found to have crossed the RPE barrier, 
possibly by endocytosis. 
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5.4.4. Conjunctival vs. choroidal clearance 
The significance of conjunctival clearance in transscleral delivery has been 
described in several reports [52,105,209].  Therefore, it was of interest to investigate 
the impact of conjunctival clearance in the absence of choroidal blood flow.  The 
model results and analysis from the previous section on the low Rc and Rp values in 
the conjunctiva demonstrate that the conjunctiva is responsible for clearing some of 
the drug, but is not as significant as clearance by the choroid.  The results from the 
unidirectional implant show that having an impermeable boundary between the drug 
and the conjunctiva will help to decrease the rate of mass clearance.  However, 
unidirectionality is not sufficient for delivering higher drug amounts to the choroid 
and retina.  Using a sustained-release formulation in addition to a unidirectional 
implant may help to increase delivery of drugs to the posterior segment. 
 
 5.5. Conclusion 
The model results in vivo and post mortem showed similar trends found from 
MRI experiments for subconjunctival delivery of Gd-DTPA by injection.  Useful 
information regarding the contributions of various clearance mechanisms on drug 
elimination and delivery could be studied by analyzing the model results.  The most 
significant barrier to successful transscleral drug delivery may be the choroidal 
circulation, and delivery methods that can overcome this barrier may yield 
significantly high drug levels in the retina. 
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Chapter 6: Summary and Recommendations for Future Work 
6.1. Project Summary 
Several objectives were achieved in this work.  First, drug delivery by the 
transscleral route was assessed by using a pharmacokinetic imaging method, DCE-
MRI.  Sustained transscleral delivery was evaluated by using continuous infusions of 
Gd-DTPA either subconjunctivally or intrasclerally.  Intrascleral infusion enabled 
Gd-DTPA to move to the macular region by traveling through the suprachoroidal 
space.  Gd-DTPA was not detected in the choroid/retina after subconjunctival 
infusions.  Sustained release delivery systems may yield more effective drug delivery 
to the retina after intrascleral administration rather than subconjunctival. 
DCE-MRI was evaluated as a pharmacokinetic imaging tool for assessing 
drug delivery in the eye.  There are current limitations in spatial and temporal 
resolution that need to be considered in order to correctly measure the desired 
outcomes by MR imaging.  There is also some concern when trying to measure 
concentration levels in tissues since standardized tissue phantoms are currently 
lacking.  Continued improvements in coil design, magnet systems, and MR sequences 
amongst other advances may help to further the capability and reliability of DCE-
MRI as a pharmacokinetic imaging tool.       
Despite current limitations in MR imaging, DCE-MRI was successfully used 
to investigate drug elimination kinetics after subconjunctival delivery.  Basic 
concepts such as the rate of drug clearance and drug retention in the subconjunctival 
depot have not been investigated due to the difficulty in acquiring concentration 
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measurements in vivo.  Using DCE-MRI, data was acquired for subconjunctival 
injections of Gd-DTPA and Gd-albumin and it was determined that lymphatic flow 
may not be a significant contributor to drug clearance.  Larger injection volumes also 
decreased the rate of mass clearance and allowed for longer retention times of drug in 
the depot. 
A distributed pharmacokinetic model for subconjunctival injection was built 
using the finite element method and the results compared with the experimental 
results from MRI.  The model results were comparable to MRI results, and further 
analysis of the model yielded additional information regarding the contributions of 
various clearance mechanisms in the eye.  Increasing the permeability of the RPE 
produced higher levels of drug in the retina compared to increasing the permeability 
of the sclera.  In light of this model result and the experimental results from Chapter 
3, efforts to increase the permeability of drug formulations through the RPE may 
yield more effective results in terms of delivery to the retina rather than utilizing 
sustained release formulations from the subconjunctival space.  Also, the use of drug 
encapsulated particles may also allow greater delivery to the retina since an increase 
in drug size will decrease clearance by the choroidal circulation. 
 
6.2.  Recommendations for Future Work 
 For future study, the use of a second measurement technique is recommended 
to obtain data that cannot be acquired with MRI, due to the limitations in the DCE-
MRI technique.  MRI provides good anatomical information but lacks sensitivity at 
the molecular level.  This can be investigated using another imaging modality in 
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conjunction with MRI such as PET or MRS.  This will dramatically expand the 
capability of imaging tools for use in drug delivery as small drug targets can now be 
assessed in vivo. 
 The results from this work pertain only to hydrophilic substances since only 
Gd-DTPA and Gd-albumin have been investigated as model drugs.  However, many 
ophthalmic drugs are lipophilic and are not water soluble.  It would be of interest to 
investigate the effects of a lipophilic contrast agent and compare the results to this 
study.  This is difficult to accomplish however, since water insoluble contrast agents 
are not manufactured as aqueous solubility is desired in the clinical setting.  It would 
also be beneficial to image an actual drug molecule and not a contrast agent, since the 
drug and contrast agent may exhibit different behavior in terms of metabolism, 
absorption and clearance.  It may be worthwhile to conduct a study to conjugate Gd 
or another paramagnetic ion to a drug molecule for MR imaging. 
Similarly, the pharmacokinetic model may be adjusted to give results for 
lipophilic substances.  The diffusion coefficients and clearance values can be altered 
to study the effect of larger therapeutic proteins as well.  The current model only 
includes the effect of static barriers and clearance by blood flow.  As discussed in 
Chapter 1, many other barriers exist, such as bulk fluid flows, metabolism and active 
transport.  It would be more difficult to correctly account for these barriers in the 
model since very few experiments have been conducted to measure these effects.  
However, the increased use of in vivo imaging modalities may enable the ability to 
acquire parameters that can be used to build more accurate pharmacokinetic models.  
Advances in pharmacokinetic imaging tools in parallel with pharmacokinetic 
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modeling may help to address the enormous need for effective delivery methods in 
the eye.  
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Chapter 7: Appendix  
 
Calculation of diffusion coefficients 
 
1. Calculation of the diffusion coefficient of Gd-DTPA (590 Da) in water at 37°C 
 
Using the correlation for dilute aqueous binary diffusion coefficients at 25°C 
(Handbook of Physics & Chemistry, 75th Ed. Pg. 6-253): 
 
494.0525 225.910 −°∞ ×=× MWD
C     (1) 
 
where D is in cm2/s.  For Gd-DTPA, 
 
494.0525 590225.910 −°∞ ×=×
CD  
 
smD C /96.3 21025 −°∞ =  
 
The diffusion coefficient at 37°C can be determined using Trout’s rule correction: 
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2.  Calculation of the diffusion coefficient of Gd-DTPA in ocular tissues 
 
The diffusion coefficient of solutes in brain tissue is estimated by: 
2λ
∞=
DDe       (3) 
 
where λ=1.6 for brain tissue.  Therefore, 
 
smsmDe /07.26.1
/3.5 210
2
210
−
−
==  
 
for Gd-DTPA in brain tissue.  The volume void fraction of brain tissue is 0.21 
[213].  The diffusion coefficients of other tissues can be calculated by a relation of the 
void fractions [188]: 
 
b
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For example, the diffusion coefficient of Gd-DTPA in sclera is: 
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The remaining diffusion coefficients for various ocular tissues are tabulated in 
Table 5-3. 
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